

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 4
APRIL 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 4

April 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 04
April 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187) and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 076752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187) and Levothyroxine Sodium (Merck KGAA ANDA 076752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBOTT	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHROID	LLOYD	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination

product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)			
MULTISOURCE	14487 (84.5%)	14558 (84.4%)			
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)			
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)			
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)			
NEW MOLECULAR ENTITIES APPROVED	28	9			
NUMBER OF APPLICANTS	1011	1007			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
ACETAMINOPHEN

AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA
		OFIRMEV					
AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@	INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jan CAHN
@	SUN PHARM INDS	325MG;50MG;40MG	A040601	001	Jul 29, 2005	Jan CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

>D>	AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Apr CAHN
>A>	AB	+	ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	SUN PHARM INDS	300MG;60MG	A089673	001	Feb 10, 1988	Mar CAHN
---	----------------	------------	---------	-----	--------------	----------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

ZYFREL

>A>	AA		CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016	Apr NEWA
-----	----	--	-------------------	-----------------------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA		AMNEAL PHARMS NY	325MG;7.5MG	A040746	002	May 10, 2016	Apr NEWA
	AA		RHODES PHARMS	325MG;5MG	A202991	001	Apr 12, 2016	Mar NEWA
	AA			325MG;7.5MG	A202991	002	Apr 12, 2016	Mar NEWA
	AA			325MG;10MG	A202991	003	Apr 12, 2016	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

	AA		ALVOGEN MALTA	325MG;5MG	A202677	003	Mar 08, 2016	Feb NEWA
	AA			325MG;7.5MG	A202677	001	Jul 26, 2012	Jan CAHN
	AA			325MG;10MG	A202677	002	Jul 26, 2012	Jan CAHN
>A>	AA		AMNEAL PHARMS NY	325MG;7.5MG	A040778	002	Jun 27, 2014	Apr NEWA
	AA		MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
	AA			325MG;5MG	A090177	002	Oct 20, 2008	Feb CAHN
	AA			325MG;7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
	AA			325MG;10MG	A090177	004	Oct 20, 2008	Feb CAHN
		@		500MG;7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
		@		650MG;10MG	A090177	006	Oct 20, 2008	Feb CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar NEWA
----	--	------------------	-------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP		AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT;ORAL

CETYLEV

		ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan NEWA
	+		2.5GM	N207916	002	Jan 29, 2016	Jan NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

	+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994	Mar CAHN
--	---	---------------------	----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

	@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb DISC
AB	ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

>A> AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr NEWA
--------	--------------------	----	---------	-----	--------------	----------

TABLET;BUCCAL

SITAVIG

+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan CAHN
---	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

ACYCLOVIR

@	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Feb DISC
---	--------------------	-------	---------	-----	--------------	----------

@		800MG	A074980	002	Sep 30, 1998	Feb DISC
---	--	-------	---------	-----	--------------	----------

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997	Feb DISC
---	-------------	--------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997	Feb DISC
---	--	------------------	---------	-----	--------------	----------

ACYCLOVIR SODIUM

>D>	@ BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Apr CAHN
-----	-----------	--------------------	---------	-----	--------------	----------

@		EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb DISC
---	--	--------------------	---------	-----	--------------	----------

>D>	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr CAHN
-----	---	------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb DISC
---	--	------------------	---------	-----	--------------	----------

AP	+	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb CTEC
----	---	------------------	---------	-----	--------------	----------

>A>	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Apr CAHN
-----	----------------------	--------------------	---------	-----	--------------	----------

>A>	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr CAHN
-----	---	------------------	---------	-----	--------------	----------

AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb NEWA
----	------------------	--------------------	---------	-----	--------------	----------

+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb CRLD
---	--	------------------	---------	-----	--------------	----------

AP		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb NEWA
----	--	------------------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

>D> AP	BEDFORD	3MG/ML	A076404	001	Jun 16, 2004	Apr CAHN
--------	---------	--------	---------	-----	--------------	----------

>A> AP	EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Apr CAHN
--------	--------------------	--------	---------	-----	--------------	----------

SOLUTION;IV (INFUSION)

ADENOSCAN

>D> AP	+	ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Apr DISC
--------	---	----------	--------------------	---------	-----	--------------	----------

>A>	@	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Apr DISC
-----	---	--------------------	---------	-----	--------------	----------

>D> AP	+	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Apr DISC
--------	---	--------------------	---------	-----	--------------	----------

>A>	@	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Apr DISC
-----	---	--------------------	---------	-----	--------------	----------

ADENOSINE

>D> AP	TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr CRLD
--------	-----------------	--------------------	---------	-----	--------------	----------

>A> AP	+	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr CRLD
--------	---	--------------------	---------	-----	--------------	----------

>D> AP		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr CRLD
--------	--	--------------------	---------	-----	--------------	----------

>A> AP	+	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr CRLD
--------	---	--------------------	---------	-----	--------------	----------

ALBUTEROL SULFATE

SOLUTION;INHALATION

ALBUTEROL SULFATE

@	HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar DISC
---	----------------	----------------	---------	-----	--------------	----------

@	LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar DISC
---	---------------	----------------	---------	-----	--------------	----------

@	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar DISC
---	--------------	----------------	---------	-----	--------------	----------

AN	+	NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar CRLD
----	---	---------	----------------	---------	-----	--------------	----------

@	TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar DISC
---	-------------	----------------	---------	-----	--------------	----------

@	WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar DISC
---	-----------------	----------------	---------	-----	--------------	----------

TABLET;ORAL

ALBUTEROL SULFATE

AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar CAHN
----	----------------	-------------	---------	-----	--------------	----------

AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar CAHN
----	--	-------------	---------	-----	--------------	----------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB	UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan NEWA
----	------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar CAHN
AB	ZYLOPRIM					
AB	SEBELA IRELAND LTD	100MG	N016084	001		Jan CAHN
AB	+	300MG	N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ ACTAVIS LABS FL INC 0.5MG

A077198 001 May 13, 2010 Jan DISC

@ 1MG

A077198 002 May 13, 2010 Jan DISC

@ 2MG

A077198 003 May 13, 2010 Jan DISC

@ 3MG

A077198 004 May 13, 2010 Jan DISC

@ COREPHARMA 0.5MG

A077996 001 Jan 31, 2007 Mar DISC

@ 1MG

A077996 002 Jan 31, 2007 Mar DISC

@ 2MG

A077996 003 Jan 31, 2007 Mar DISC

@ 3MG

A077996 004 Jan 31, 2007 Mar DISC

@ IMPAX LABS 0.5MG

A077968 004 May 24, 2007 Jan DISC

@ 1MG

A077968 003 May 24, 2007 Jan DISC

@ 2MG

A077968 002 May 24, 2007 Jan DISC

@ 3MG

A077968 001 May 24, 2007 Jan DISC

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN

SUPPOSITORY; URETHRAL

MUSE

	+ MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
	+	0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
	+	0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>A>	AP	SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA
-----	----	---------------	------------------	---------	-----	--------------	----------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML;	N020678	005	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

INJECTABLE; INJECTION

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
217MG/100ML;112MG/100ML						
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar CMS1

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE						
AB	@ SUN PHARM INDS INC	10MG	A 040816	002	Jun 27, 2008	Mar DISC
	@	10MG	A 089399	002	Jul 14, 1987	Mar DISC
		10MG	A 089399	002	Jul 14, 1987	Mar CAHN
	@	25MG	A 040816	001	Jun 27, 2008	Mar DISC
AB	@	25MG	A 089399	001	Jul 14, 1987	Mar DISC
		25MG	A 089399	001	Jul 14, 1987	Mar CAHN
AB	@	50MG	A 040816	003	Jun 27, 2008	Mar DISC
	@	50MG	A 089399	003	Jul 14, 1987	Mar DISC
		50MG	A 089399	003	Jul 14, 1987	Mar CAHN
	@	75MG	A 040816	004	Jun 27, 2008	Mar DISC
AB	@	75MG	A 089399	004	Jul 14, 1987	Mar DISC
		75MG	A 089399	004	Jul 14, 1987	Mar CAHN
AB	@	100MG	A 040816	005	Jun 27, 2008	Mar DISC
	@	100MG	A 089399	005	Jul 14, 1987	Mar DISC
		100MG	A 089399	005	Jul 14, 1987	Mar CAHN
	@	150MG	A 040816	006	Jun 27, 2008	Mar DISC
AB	@	150MG	A 089399	006	Jul 14, 1987	Mar DISC
		150MG	A 089399	006	Jul 14, 1987	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ SUN PHARM INDS	EQ 12.5MG BASE; 5MG	A070765	001	Dec 10, 1986	Mar CAHN
@	EQ 25MG BASE; 10MG	A070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG; 2MG	A071077	001	Nov 12, 1986	Mar CAHN
@		10MG; 4MG	A071078	001	Nov 12, 1986	Mar CAHN
@		25MG; 2MG	A070297	001	Nov 12, 1986	Mar CAHN
@		25MG; 4MG	A071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb CAHN
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb CAHN
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb CAHN
	@ SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar CAHN
	@	EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar CAHN
	@	EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>A>	AB	AUROBINDO PHARMA LTD	EQ 5MG BASE; 160MG	A206512	001	Apr 22, 2016	Apr NEWA
>A>	AB		EQ 5MG BASE; 320MG	A206512	002	Apr 22, 2016	Apr NEWA
>A>	AB		EQ 10MG BASE; 160MG	A206512	003	Apr 22, 2016	Apr NEWA
>A>	AB		EQ 10MG BASE; 320MG	A206512	004	Apr 22, 2016	Apr NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

>D>	AB	PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr CRLD
>A>	AB	+	EQ 12% BASE	A075774	001	May 01, 2002	Apr CRLD
>D>		LAC-HYDRIN					
>D>	AB	+	RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996
>A>		@	EQ 12% BASE	N020508	001	Aug 29, 1996	Apr DISC

LOTION; TOPICAL

AMMONIUM LACTATE

>D>	AB	PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr CRLD
>A>	AB	+	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr CRLD
>D>		LAC-HYDRIN					
>D>	AB	+	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985
>A>		@	EQ 12% BASE	N019155	001	Apr 24, 1985	Apr DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb DISC
@		500MG	A065016	002	Apr 08, 1999	Feb DISC

TABLET; ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb DISC
@		875MG	A065059	002	Nov 24, 2000	Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb DISC
@		250MG	A065021	002	Dec 23, 1999	Feb DISC

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008	Jan CAHN
---	----------------------	-------	---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb DISC
----------------------	---------------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb DISC
@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb DISC

AUGMENTIN '125'

DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Mar CTEC
--------------------	-----------------------	---------	-----	--------------	----------

AUGMENTIN '250'

+ DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Mar CRLD
----------------------	----------------------	---------	-----	--------------	----------

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan NEWA
	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan NEWA
	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan NEWA
	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan NEWA
	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan NEWA
	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

>D>	AMPHOTEC					
>D>	+ ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
>A>	@	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
>D>	+	100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC
>A>	@	100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

ARIPIRAZOLE

SOLUTION; ORAL

ARIPIRAZOLE

AA	+ AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	-----------------	--------	---------	-----	--------------	----------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

>D>	@ MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr	CMFD
>A> AB		50MG	A200043	001	Jun 01, 2012	Apr	CMFD
>D>	@	150MG	A200043	002	Jun 01, 2012	Apr	CMFD
>A> AB		150MG	A200043	002	Jun 01, 2012	Apr	CMFD
>D>	@	250MG	A200043	003	Jun 01, 2012	Apr	CMFD
>A> AB		250MG	A200043	003	Jun 01, 2012	Apr	CMFD

NUVIGIL

>D>	CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr	CTEC
>A> AB		50MG	N021875	001	Jun 15, 2007	Apr	CTEC
>D>		150MG	N021875	003	Jun 15, 2007	Apr	CTEC
>A> AB		150MG	N021875	003	Jun 15, 2007	Apr	CTEC
>D>	+	250MG	N021875	004	Jun 15, 2007	Apr	CTEC
>A> AB	+	250MG	N021875	004	Jun 15, 2007	Apr	CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC

325MG; 50MG; 40MG

A078149 001 Jun 13, 2007 Jan CAHN

FIORINAL

>D> AA	+	ACTAVIS LABS UT INC	325MG; 50MG; 40MG	N017534	005	Apr 16, 1986	Apr	CAHN
>A> AA	+	ALLERGAN SALES LLC	325MG; 50MG; 40MG	N017534	005	Apr 16, 1986	Apr	CAHN

TABLET; ORAL

FIORINAL

>D>	@	ACTAVIS LABS UT INC	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986	Apr	CAHN
>A>	@	ALLERGAN SALES LLC	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986	Apr	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE

>D> AB	+	ACTAVIS LABS UT INC	325MG; 50MG; 40MG; 30MG	N019429	003	Oct 26, 1990	Apr	CAHN
>A> AB	+	ALLERGAN SALES LLC	325MG; 50MG; 40MG; 30MG	N019429	003	Oct 26, 1990	Apr	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB

INGENUS PHARMS NJ

325MG; 200MG

A040832 001 Jan 07, 2010 Jan CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB

INGENUS PHARMS NJ

325MG; 200MG; 16MG

A040860 001 Jan 07, 2010 Mar CMFD

@

325MG; 200MG; 16MG

A040860 001 Jan 07, 2010 Jan CAHN

AB

+

SANDOZ

325MG; 200MG; 16MG

A040118 001 Apr 16, 1996 Mar CTEC

+

325MG; 200MG; 16MG

A040118 001 Apr 16, 1996 Jan CRLD

SOMA COMPOUND W/ CODEINE

@ MEDA PHARMS

325MG; 200MG; 16MG

N012366 002 Jul 11, 1983 Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

>D> AB		AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	Apr	DISC
>A>	@		25MG; 200MG	A206392	001	Mar 08, 2016	Apr	DISC
AB			25MG; 200MG	A206392	001	Mar 08, 2016	Feb	NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

@ SUN PHARM INDS

325MG; 4.5MG; 0.38MG

A040260 001 Jul 17, 1998 Mar CAHN

@

325MG; 4.5MG; 0.38MG

A087794 001 May 26, 1982 Mar CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB ALVOGEN MALTA

25MG

A073646 001 Jul 31, 1992 Jan CAHN

AB

50MG

A072303 001 Jul 15, 1988 Jan CAHN

AB

100MG

A072304 001 Jul 15, 1988 Jan CAHN

TENORMIN

AB ALVOGEN MALTA

25MG

N018240 004 Apr 09, 1990 Jan CAHN

AB

50MG

N018240 001 Jan CAHN

AB +

100MG

N018240 002 Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB ALVOGEN MALTA

50MG; 25MG

A072301 001 May 31, 1990 Jan CAHN

AB

100MG; 25MG

A072302 001 May 31, 1990 Jan CAHN

AB SUN PHARM INDS

100MG; 25MG

A073582 001 Apr 29, 1993 Mar CAHN

TENORETIC 100

AB + ALVOGEN MALTA

100MG; 25MG

N018760 001 Jun 08, 1984 Jan CAHN

TENORETIC 50

AB ALVOGEN MALTA

50MG; 25MG

N018760 002 Jun 08, 1984 Jan CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ SUN PHARM INDS

0.025MG; 2.5MG

A085506 001 Mar CAHN

AURANOFIN

CAPSULE; ORAL

RIDAURA

+ SEBELA IRELAND LTD 3MG

N018689 001 May 24, 1985 Jan CAHN

AXITINIB

TABLET; ORAL

INLYTA

>A> PF PRISM CV

1MG

N202324 001 Jan 27, 2012 Apr CAHN

>A> +

5MG

N202324 002 Jan 27, 2012 Apr CAHN

>D> PFIZER

1MG

N202324 001 Jan 27, 2012 Apr CAHN

>D> +

5MG

N202324 002 Jan 27, 2012 Apr CAHN

AZACITIDINE

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A> AP MYLAN INSTITUTIONAL 100MG/VIAL

A204949 001 Apr 28, 2016 Apr NEWA

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

>A> ACTAVIS LLC 100MG/VIAL

N208216 001 Apr 29, 2016 Apr NEWA

AZATHIOPRINE

TABLET; ORAL

IMURAN

AB + SEBELA IRELAND LTD

25MG

N016324 002 Jan CAHN

AB +

50MG

N016324 001 Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

@ SEBELA IRELAND LTD

EQ 100MG BASE/VIAL

N017391 001 Jan CAHN

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jan CAHN
+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan CAHN
+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan CAHN

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

>D> AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Apr CTEC
>A> BX		EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Apr CTEC
>D> AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Apr CTEC
>A> BX		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Apr CTEC

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

@ EUROHLTH INTL SARL

1GM/VIAL

A065286 001 Mar 23, 2011 Mar DISC

@

2GM/VIAL

A065286 002 Mar 23, 2011 Mar DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

>A> AP	SINTETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Apr NEWA
>A> AP		0.5MG/ML	A091193	002	May 03, 2016	Apr NEWA
>A> AP		2MG/ML	A091193	003	May 03, 2016	Apr NEWA

TABLET; ORAL

BACLOFEN

AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan NEWA
----	--------------------	------	---------	-----	--------------	----------

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan NEWA
---	--------	--------------	---------	-----	--------------	----------

SUSPENSION; ORAL

READI-CAT 2

+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
---	--------	----------------	---------	-----	--------------	----------

READI-CAT 2 SMOOTHIES

BRACCO 2% (9GM/450ML)

N208143 002 Jan 15, 2016 Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC

5MG

A076267 001 Feb 11, 2004 Jan DISC

@

10MG

A076267 002 Feb 11, 2004 Jan DISC

@

20MG

A076267 003 Feb 11, 2004 Jan DISC

@

40MG

A076267 004 Feb 11, 2004 Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ACTAVIS LABS FL INC

5MG; 6.25MG

A076342 001 Feb 11, 2004 Jan DISC

@

10MG; 12.5MG

A076342 002 Feb 11, 2004 Jan DISC

@

20MG; 12.5MG

A076342 003 Feb 11, 2004 Jan DISC

@

20MG; 25MG

A076342 004 Feb 11, 2004 Jan DISC

@ IVAX SUB TEVA PHARMS

5MG; 6.25MG

A076348 001 Feb 11, 2004 Mar DISC

@

10MG; 12.5MG

A076348 002 Feb 11, 2004 Mar DISC

@

20MG; 12.5MG

A076348 003 Feb 11, 2004 Mar DISC

@

20MG; 25MG

A076348 004 Feb 11, 2004 Mar DISC

@ SUN PHARM INDS LTD

5MG; 6.25MG

A077483 001 Sep 08, 2005 Mar DISC

@

10MG; 12.5MG

A077483 002 Sep 08, 2005 Mar DISC

@

20MG; 12.5MG

A077483 003 Sep 08, 2005 Mar DISC

@

20MG; 25MG

A077483 004 Sep 08, 2005 Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP		GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar NEWA
AP			100MG/VIAL	A204771	002	Mar 24, 2016	Mar NEWA
AP		INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar NEWA
AP			100MG/VIAL	A205476	002	Mar 24, 2016	Mar NEWA
		TREANDA					
AP	+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar CFTG
AP	+		100MG/VIAL	N022249	001	Mar 20, 2008	Mar CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA		BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

	+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Feb CAHN
--	---	---------	--------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

	@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar DISC
--	---	------------	------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

	+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb NEWA
--	---	--------------------	---------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894	001	Oct 30, 2015	Mar CAHN
----	--	-----------------	-------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan CAHN
----	--	---------------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@	IMPAX LABS	5MG	A040739	001	Nov 01, 2006	Mar DISC
	@		10MG	A040741	001	Nov 01, 2006	Mar DISC
	@		25MG	A040740	001	Nov 01, 2006	Mar DISC
	@		50MG	A040721	004	Nov 01, 2006	Mar DISC

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

>A>	AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr NEWA
-----	----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

	@	SEBELA IRELAND LTD	262.4MG, N/A, N/A, N/A, 250MG, N/A, N/A, N/A, 500MG	N050719	001	Aug 15, 1996	Jan CAHN
--	---	--------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

	@	SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Mar CAHN
	@		10MG	A075474	002	Oct 25, 2002	Mar CAHN

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+ UCB INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
-----------	--------------------	---------	-----	--------------	----------

SOLUTION;ORAL

BRIVIACT

+ UCB INC	10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA
-----------	---------	---------	-----	--------------	----------

TABLET;ORAL

BRIVIACT

UCB INC	10MG	N205836	001	Feb 18, 2016	Feb NEWA
	25MG	N205836	002	Feb 18, 2016	Feb NEWA
	50MG	N205836	003	Feb 18, 2016	Feb NEWA
	75MG	N205836	004	Feb 18, 2016	Feb NEWA
+	100MG	N205836	005	Feb 18, 2016	Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMSITE

>A> + INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr NEWA
-------------------------	----------------	---------	-----	--------------	----------

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB + MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
------------	-------------	---------	-----	--------------	----------

PARLODEL

@ US PHARMS HOLDINGS I EQ 5MG BASE

N017962	002	Mar 01, 1982	Jan DISC
---------	-----	--------------	----------

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB + PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
------------------	---------------	---------	-----	--------------	----------

AB SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
---------------	---------------	---------	-----	--------------	----------

PARLODEL

>D> @ US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr CMFD
----------------------------	---------------	---------	-----	--	----------

>A> AB	EQ 2.5MG BASE	N017962	001		Apr CMFD
--------	---------------	---------	-----	--	----------

@ EQ 2.5MG BASE

N017962	001		Jan DISC
---------	-----	--	----------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar NEWA
----------------------	-----	---------	-----	--------------	----------

ENTOCORT EC

AB + ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
---------------------------	-----	---------	-----	--------------	----------

SUSPENSION;INHALATION

BUDESONIDE

AN TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA
--------------------	---------	---------	-----	--------------	----------

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

>D> AP + BEDFORD	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN
------------------	-----------	---------	-----	--------------	----------

>A> AP + EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN
-----------------------------	-----------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
-----------------------	-------------	---------	-----	--------------	----------

AB	EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA
----	-------------	---------	-----	--------------	----------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1 INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
--------------------	-------	---------	-----	--------------	----------

AB1	150MG	A206674	002	Feb 09, 2016	Jan NEWA
-----	-------	---------	-----	--------------	----------

AB1	200MG	A206674	003	Feb 09, 2016	Jan NEWA
-----	-------	---------	-----	--------------	----------

AB1 SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
------------------------	-------	---------	-----	--------------	----------

AB1	150MG	A205794	002	Mar 01, 2016	Feb NEWA
-----	-------	---------	-----	--------------	----------

AB1	200MG	A205794	003	Mar 01, 2016	Feb NEWA
-----	-------	---------	-----	--------------	----------

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CONTRAVE

>A>	+	OREXIGEN	90MG; 8MG	N200063	001	Sep 10, 2014	Apr CAHN
>D>	+	TAKEDA PHARMS USA	90MG; 8MG	N200063	001	Sep 10, 2014	Apr CAHN

BUSULFAN

INJECTABLE; INJECTION
BUSULFAN

AP		LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	--	---------------------	--------	---------	-----	--------------	----------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

>D>	AP	BEDFORD	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
		@ CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan CAHN
>A>	AP	EUROHLTH INTL SARL	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE					
>D>	AP	BEDFORD	1MG/ML	A075045	001	Aug 12, 1998	Apr CAHN
>D>	AP		2MG/ML	A075045	002	Aug 12, 1998	Apr CAHN
		@ CLARIS	1MG/ML	A075695	001	Oct 23, 2001	Mar CAHN
		@	2MG/ML	A075695	002	Oct 23, 2001	Mar CAHN
>A>	AP	EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Apr CAHN
>A>	AP		2MG/ML	A075045	002	Aug 12, 1998	Apr CAHN

CABERGOLINE

TABLET; ORAL
CABERGOLINE

	@	IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar DISC
--	---	----------------	-------	---------	-----	--------------	----------

>A> CABOZANTINIB S-MALATE

>A> TABLET; ORAL
>A> CABOMETYX

>A>		EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016	Apr NEWA
>A>			EQ 40MG BASE	N208692	002	Apr 25, 2016	Apr NEWA
>A>	+		EQ 60MG BASE	N208692	003	Apr 25, 2016	Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

+		HORIZON PHARMA	100MG; 2MG	A086557	001	Oct 04, 1983	Jan CAHN
---	--	----------------	------------	---------	-----	--------------	----------

CALCIPOTRIENE

CREAM; TOPICAL
CALCIPOTRIENE

AB		GLENMARK PHARMS	0.005%	A205772	001	Jun 09, 2015	Mar CAHN
----	--	-----------------	--------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

AB		BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB			0.5MCG	A091174	002	May 24, 2013	Jan CAHN

INJECTABLE; INJECTION
CALCITRIOL

		AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb CTEC
	@	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

		DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	@	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb DISC
		DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	@	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb DISC
		DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	@	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb DISC
		DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	@	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb DISC

SOLUTION;INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC
--------------------	--	---------	-----	--------------	----------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar DISC
@	25MG	A074737	002	Oct 28, 1998	Mar DISC
@	50MG	A074737	003	Oct 28, 1998	Mar DISC
@	100MG	A074737	004	Oct 28, 1998	Mar DISC
@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC
@	25MG	A074363	002	Nov 09, 1995	Jan DISC
@	50MG	A074363	003	Nov 09, 1995	Jan DISC
@	100MG	A074363	004	Nov 09, 1995	Jan DISC
@ STASON	12.5MG	A074677	004	May 30, 1997	Mar DISC
@	25MG	A074677	002	May 30, 1997	Mar DISC
@	50MG	A074677	001	May 30, 1997	Mar DISC
@	100MG	A074677	003	May 30, 1997	Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN
AB		200MG	A076697	002	May 20, 2011	Jan CAHN
AB		300MG	A076697	003	May 20, 2011	Jan CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb NEWA
----	-------------------	------	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

>D>	AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr DISC
>A>	@		50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr DISC
>D>	AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr DISC
>A>	@		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr DISC
>D>	AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr DISC
>A>	@		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr DISC
>D>	AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr DISC
>A>	@		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr DISC
	AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb CAHN
	AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb CAHN
	AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb CAHN
	AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar NEWA
	AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar NEWA
	AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar NEWA

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

+	ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Feb CAHN
---	-------------	-----------	---------	-----	--------------	----------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan CAHN
----	-------------------	-------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

@ SUN PHARM INDS LTD

EQ 125MG BASE/5ML

A065115 001 Mar 26, 2003 Feb DISC

@

EQ 250MG BASE/5ML

A065115 002 Mar 26, 2003 Feb DISC

@

EQ 500MG BASE/5ML

A065115 003 Mar 26, 2003 Feb DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan NEWA
----	-------------	------------------	---------	-----	--------------	----------

>D> CEFDITOREN PIVOXIL

>D> TABLET; ORAL

>D> SPECTRACEF

>D> VANSSEN PHARMA

200MG

N021222 001 Aug 29, 2001 Apr DISC

>A> @

200MG

N021222 001 Aug 29, 2001 Apr DISC

>D> +

400MG

N021222 002 Jul 21, 2008 Apr DISC

>A> @

400MG

N021222 002 Jul 21, 2008 Apr DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan NEWA
----	-------------------	--------------------	---------	-----	--------------	----------

AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan NEWA
----	--	------------------	---------	-----	--------------	----------

AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan NEWA
----	--	------------------	---------	-----	--------------	----------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
----	-------------	------------------	---------	-----	--------------	----------

AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
----	--	------------------	---------	-----	--------------	----------

CLAFORAN

AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
----	---------------------	--------------------	---------	-----	--	----------

AP	+ US PHARM HOLDINGS	EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
----	---------------------	------------------	---------	-----	--	----------

AP	+ US PHARM HOLDINGS	EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
----	---------------------	------------------	---------	-----	--	----------

AP	+ US PHARM HOLDINGS	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
----	---------------------	-------------------	---------	-----	--------------	----------

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan CAHN
--	---------------------	-----------------	---------	-----	--------------	----------

	+ US PHARM HOLDINGS	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
--	---------------------	-----------------	---------	-----	--------------	----------

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
--	---------------------	-----------------	---------	-----	--------------	----------

	@ US PHARM HOLDINGS	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN
--	---------------------	-----------------	---------	-----	--------------	----------

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

@ TELIGENT PHARMA INC

EQ 1GM BASE/VIAL

A063293 001 Apr 29, 1993 Jan CAHN

AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
----	--	------------------	---------	-----	--------------	----------

	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
--	---	------------------	---------	-----	--------------	----------

	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
--	---	------------------	---------	-----	--------------	----------

AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
----	--	------------------	---------	-----	--------------	----------

	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
--	---	------------------	---------	-----	--------------	----------

	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN
--	---	-------------------	---------	-----	--------------	----------

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

@ SUN PHARM INDS LTD

EQ 50MG BASE/5ML

A065082 001 May 31, 2002 Feb DISC

@

EQ 100MG BASE/5ML

A065082 002 May 31, 2002 Feb DISC

TABLET; ORAL

CEFPODOXIME PROXETIL

@ SUN PHARM INDS LTD

EQ 100MG BASE

A065083 001 Aug 20, 2003 Feb DISC

@

EQ 200MG BASE

A065083 002 Aug 20, 2003 Feb DISC

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

>D>	AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr DISC
>A>		@	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr DISC
>D>	AP		EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr DISC
>A>		@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr DISC
>D>	AP		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr DISC
>A>		@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr DISC
>D>	AP		EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr DISC
>A>		@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr DISC
>D>		ROCEPHIN					
>D>	AP	+ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr DISC
>A>		@	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr DISC
>D>	AP	+	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr DISC
>A>		@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr DISC

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFTIN

GLAXOSMITHKLINE

+

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

@

TABLET; ORAL

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

@

@

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

EQ 125MG BASE

EQ 250MG BASE

EQ 500MG BASE

N050672 001 Jun 30, 1994 Feb CTEC

N050672 002 Apr 29, 1997 Feb CTEC

A065323 001 Feb 05, 2008 Feb DISC

A065323 002 Feb 05, 2008 Feb DISC

A065118 001 Apr 25, 2003 Feb DISC

A065118 002 Apr 25, 2003 Feb DISC

A065118 003 Apr 25, 2003 Feb DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP + IGI LABS INC

AP +

ZINACEF IN PLASTIC CONTAINER

@ IGI LABS INC

+

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB + IGI LABS INC

EQ 1.5GM BASE/VIAL

EQ 7.5GM BASE/VIAL

EQ 15MG BASE/ML

EQ 30MG BASE/ML

EQ 750MG BASE/VIAL

N050558 003 Oct 19, 1983 Jan CAHN

N050558 004 Oct 23, 1986 Jan CAHN

N050643 001 Apr 28, 1989 Jan CAHN

N050643 002 Apr 28, 1989 Jan CAHN

N050558 002 Oct 19, 1983 Jan CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB AUROBINDO PHARMA LTD

AB

AB

AB

AB

AB

AB

AB

AB

50MG

100MG

200MG

400MG

50MG

100MG

200MG

400MG

A206827 001 Feb 01, 2016 Jan NEWA

A206827 002 Feb 01, 2016 Jan NEWA

A206827 003 Feb 01, 2016 Jan NEWA

A206827 004 Feb 01, 2016 Jan NEWA

A204590 001 Mar 16, 2016 Feb NEWA

A204590 002 Mar 16, 2016 Feb NEWA

A204590 003 Mar 16, 2016 Feb NEWA

A204590 004 Mar 16, 2016 Feb NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@ SUN PHARM INDS LTD

@

FOR SUSPENSION; ORAL

KEFLEX

@ PRAGMA PHARMS LLC

@

@

EQ 250MG BASE

EQ 500MG BASE

EQ 100MG BASE/ML

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

A065007 001 Sep 16, 1999 Feb DISC

A065007 002 Sep 16, 1999 Feb DISC

N050406 003 Mar CAHN

N050406 001 Mar CAHN

N050406 002 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
>D> AA	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC
>A>	@	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan NEWA
----	----------------------	-------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS

EQ 150MG BASE

A080880 001

Mar DISC

@

EQ 300MG BASE

A040516 001 Aug 29, 2003

Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 4MG

A080961 001

Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Feb CAHN
----	------------------	----------------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC 100MG

A088725 001 Aug 31, 1984

Mar CAHN

@

250MG

A088726 001 Aug 31, 1984

Mar CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	MYLAN	25MG	A086831	002		Jan CTEC
----	-------	------	---------	-----	--	----------

AB	SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan NEWA
----	----------------	------	---------	-----	--------------	----------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC 250MG

A089852 001 May 04, 1988

Feb CAHN

@ 500MG

A089853 001 May 04, 1988

Feb CAHN

>D>	MIKART	750MG	A040861	002	Jun 01, 2010	Apr CRLD
-----	--------	-------	---------	-----	--------------	----------

>A>	+	750MG	A040861	002	Jun 01, 2010	Apr CRLD
-----	---	-------	---------	-----	--------------	----------

@ SUN PHARM INDS 500MG

A089970 001 Sep 27, 1990

Mar CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+ TAKEDA GMBH 0.08MG/INH

N021658 002 Jan 10, 2008 Jan CRLD

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

>A> SOLUTION/DROPS; OTIC

>A> OTOVEL

>A>	+	LABORATORIOS SALVAT	EQ 0.3% BASE; 0.025%	N208251	001	Apr 29, 2016	Apr NEWA
-----	---	---------------------	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC 212.6MG; EQ 287.5MG BASE

A077417 001 Nov 30, 2010

Jan DISC

@ 425.2MG; EQ 574.9MG BASE

A077809 001 Nov 30, 2010

Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS EQ 10MG BASE

A077052 001 Jul 03, 2006 Mar CAHN

@ EQ 20MG BASE

A077052 002 Jul 03, 2006 Mar CAHN

@ EQ 40MG BASE

A077052 003 Jul 03, 2006 Mar CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB ALLIED PHARMA INC 500MG

A203243 001 Feb 29, 2016 Feb NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

>D> AP BEDFORD EQ 150MG BASE/ML

A065206 001 Sep 24, 2004 Apr CAHN

>A> AP EUROHLTH INTL SARL EQ 150MG BASE/ML

A065206 001 Sep 24, 2004 Apr CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX + AQUA PHARMS LLC 1.2%; 0.025%

N050803 001 Jul 16, 2010 Jan CAHN

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS 0.05%

A074407 001 Feb 23, 1996 Mar CRLD

TEMOVATE

@ FOUGERA PHARMS 0.05%

N019323 001 Dec 27, 1985 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB + MALLINCKRODT LLC 25MG

N019906 001 Dec 29, 1989 Jan CRLD

AB 50MG

N019906 002 Dec 29, 1989 Jan CRLD

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 0.1MG

A070887 001 Aug 31, 1988 Feb CAHN

@ 0.2MG

A070886 001 Aug 31, 1988 Feb CAHN

@ 0.3MG

A071294 001 Aug 31, 1988 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB SUN PHARM INDS EQ 75MG BASE

A078133 001 Jun 10, 2013 Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

>A> @ AUROLIFE PHARMA LLC 3.75MG

A072219 001 Aug 26, 1988 Apr CAHN

@ 7.5MG

A072220 001 Aug 26, 1988 Feb CAHN

@ 15MG

A072112 001 Aug 26, 1988 Feb CAHN

>D> @ SANDOZ 3.75MG

A072219 001 Aug 26, 1988 Apr CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG

A072512 001 May 11, 1990 Mar CAHN

@ 7.5MG

A072513 001 May 11, 1990 Mar CAHN

@ 15MG

A072514 001 May 11, 1990 Feb CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA NOSTRUM LABS INC 10MG/5ML; 6.25MG/5ML

A090180 001 Mar 17, 2010 Feb CAHN

COLCHICINECAPSULE;ORAL
MITIGARE

+ HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014 Mar CRLD

COLCHICINE; PROBENECIDTABLET;ORAL
PROBENECID AND COLCHICINE

AB INGENUS PHARMS NJ 0.5MG;500MG A040618 001 May 13, 2008 Jan CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S+ ENDO PHARMS INC EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG N050356 001 Feb CAHN
BASE/ML;0.5MG/MLCORTICOTROPININJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML N008975 001 Feb CAHN

@ 80 UNITS/ML N008975 002 Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE;INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML N009854 001 Feb CAHN

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML A206503 001 Dec 11, 2015 Mar CAHN

SPRAY, METERED;NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005 Feb CAHN

CYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL N012142 003 Mar DISC

@ 1GM/VIAL N012142 004 Aug 30, 1982 Mar DISC

@ 2GM/VIAL N012142 005 Aug 30, 1982 Mar DISC

CYPROHEPTADINE HYDROCHLORIDETABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA INGENUS PHARMS NJ 4MG A205087 001 Sep 23, 2015 Jan CAHN

CYTARABINEINJECTABLE;INJECTION
CYTARABINE

AP MYLAN PHARMS INC 20MG/ML A200915 001 Dec 13, 2011 Mar CAHN

AP 20MG/ML A200916 001 Dec 13, 2011 Mar CAHN

DACLATASVIR DIHYDROCHLORIDETABLET;ORAL
DAKLINZA

>A> BRISTOL-MYERS SQUIBB EQ 90MG BASE N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCININJECTABLE;INJECTION
DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDEPOWDER;IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUM

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Feb NEWA
----	---------------------	-----------	---------	-----	--------------	----------

DAPSONE

GEL; TOPICAL
ACZONE

	+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Feb NEWA
--	---	--------------	------	---------	-----	--------------	----------

TABLET; ORAL
DAPSONE

AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Mar CAHN
AB		100MG	A205429	002	Jan 07, 2016	Mar CAHN
>A> AB	NORTH CREEK PHARMS	25MG	A204074	001	May 10, 2016	Apr NEWA
>A> AB		100MG	A204074	002	May 10, 2016	Apr NEWA
>A> AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr NEWA
>A> AB		100MG	A203887	002	May 06, 2016	Apr NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS
CUBICIN

AP	+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR
----	---	--------	------------	---------	-----	--------------	----------

DAPTOMYCIN

AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
----	--	-------------	------------	---------	-----	--------------	----------

AP		TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar NEWA
----	--	-----------------	------------	---------	-----	--------------	----------

POWDER; IV (INFUSION)
CUBICIN

	@	CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR
--	---	--------	------------	---------	-----	--------------	----------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
ENABLEX

AB		APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
----	--	------	---------------	---------	-----	--------------	----------

AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN
----	---	--	--------------	---------	-----	--------------	----------

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

AB			250MG	A203560	002	Jan 26, 2016	Jan NEWA
----	--	--	-------	---------	-----	--------------	----------

AB			500MG	A203560	003	Jan 26, 2016	Jan NEWA
----	--	--	-------	---------	-----	--------------	----------

EXJADE

AB		NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
----	--	----------	-------	---------	-----	--------------	----------

AB			250MG	N021882	002	Nov 02, 2005	Jan CFTG
----	--	--	-------	---------	-----	--------------	----------

AB	+		500MG	N021882	003	Nov 02, 2005	Jan CFTG
----	---	--	-------	---------	-----	--------------	----------

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)
DEFITELIO

	+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
--	---	-------------	-----------------------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

	@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
--	---	------------	-------	---------	-----	--------------	----------

	@		300MG	A065094	002	Mar 22, 2004	Mar DISC
--	---	--	-------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
----	--	------------------	------	---------	-----	--------------	----------

AB			25MG	A208105	002	Mar 17, 2016	Mar NEWA
----	--	--	------	---------	-----	--------------	----------

AB			50MG	A208105	003	Mar 17, 2016	Mar NEWA
----	--	--	------	---------	-----	--------------	----------

AB			75MG	A208105	004	Mar 17, 2016	Mar NEWA
----	--	--	------	---------	-----	--------------	----------

AB			100MG	A208105	005	Mar 17, 2016	Mar NEWA
----	--	--	-------	---------	-----	--------------	----------

AB			150MG	A208105	006	Mar 17, 2016	Mar NEWA
----	--	--	-------	---------	-----	--------------	----------

>A> AB		INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
--------	--	----------------	------	---------	-----	--------------	----------

>A> AB			25MG	A207433	002	May 05, 2016	Apr NEWA
--------	--	--	------	---------	-----	--------------	----------

>A> AB			50MG	A207433	003	May 05, 2016	Apr NEWA
--------	--	--	------	---------	-----	--------------	----------

>A> AB			75MG	A207433	004	May 05, 2016	Apr NEWA
--------	--	--	------	---------	-----	--------------	----------

>A> AB			100MG	A207433	005	May 05, 2016	Apr NEWA
--------	--	--	-------	---------	-----	--------------	----------

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	AB		150MG	A207433	006	May 05, 2016	Apr NEWA
		NORPRAMIN					
	AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
	AB		25MG	N014399	001		Jan CAHN
	AB		50MG	N014399	003		Jan CAHN
	AB		75MG	N014399	004		Jan CAHN
	AB	+	100MG	N014399	005		Jan CAHN
	AB		150MG	N014399	006		Jan CAHN

DESONIDE

CREAM;TOPICAL

DESONIDE

	AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan CAHN
--	----	------------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

>A>	AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr NEWA
	AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

	AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

	@	SUN PHARM INDS	0.25MG	A084013	001		Mar CAHN
	@		0.25MG	A084764	001		Mar CAHN
	@		0.5MG	A084084	001		Mar CAHN
	@		0.5MG	A084766	001		Mar CAHN
	@		0.75MG	A084081	001		Mar CAHN
	@		0.75MG	A084765	001		Mar CAHN
	@		1.5MG	A084086	001		Mar CAHN
	@		1.5MG	A084763	001		Mar CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar CTNA
----	---	--------------------	----------------------	---------	-----	--------------	----------

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

	+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan NEWA
--	---	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
		PRECEDEX					
	+	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

	AB	SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
	AB		5MG	A201231	002	Sep 24, 2015	Feb CAHN
	AB		10MG	A201231	003	Sep 24, 2015	Feb CAHN

DEXRAZOXANE HYDROCHLORIDEINJECTABLE; INJECTION
TOTECT

+ CLINIGEN HLTHCARE EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS 15MG/5ML; 6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML N017484 001 Feb CMS1

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML N018840 001 Jun 29, 1983 Feb CMS1

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL 5MG/ML A070313 001 Dec 16, 1985 Jan CAHN

TABLET; ORAL

DIAZEPAM

	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan NEWA
		5MG	A070228	003	Sep 26, 1985	Jan NEWA

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb NEWA
----	----------------	------	---------	-----	--------------	----------

ZIPSOR

AB	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb CFTG
----	---------------	------	---------	-----	--------------	----------

FOR SOLUTION; ORAL

CAMBIA

>D>	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr CFTG
>A> AB	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr CFTG

DICLOFENAC POTASSIUM

>A> AB	PAR FORM	50MG	A202964	001	May 02, 2016	Apr NEWA
--------	----------	------	---------	-----	--------------	----------

TABLET; ORAL

CATAFLAM

@ NOVARTIS

DICLOFENAC POTASSIUM

AB	+ MYLAN	50MG	A075463	001	Jul 26, 1999	Mar CRLD
----	---------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar NEWA
>A> AB	TARO	3%	A206298	001	Apr 28, 2016	Apr NEWA

VOLTAREN

AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CFTG
----	------------------------	----	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT		RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		DICLOFENAC SODIUM					
AB	+	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb CRLD
		VOLTAREN-XR					
		@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB		EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

@ SUN PHARM INDS 10MG

A084505 001 Oct 21, 1986 Mar CAHN

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP		EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar CMS1
		SYRUP;ORAL					
		BENTYL					
		@ APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Jan DISC
		DICYCLOMINE HYDROCHLORIDE					
	+	MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan CRLD
		TABLET;ORAL					
		DICYCLOMINE HYDROCHLORIDE					
		@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar CAHN

DIENOEST; ESTRADIOL VALERATE

TABLET;ORAL

ESTRADIOL VALERATE AND DIENOEST

>A>							
>A>	AB	WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	A202349	001	May 06, 2016	Apr NEWA
		G, N/A					
		NATAZIA					
>D>	+	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr CFTG
		G, N/A					
>A>	AB	+	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr CFTG
		G, N/A					

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

@ COREPHARMA 25MG

A040828 001 Nov 05, 2008 Mar DISC

TENUATE

>A>	AA	+	ACTAVIS LABS UT INC	25MG	N011722	002	Apr CAHN
>D>	AA	+	ALLERGAN SALES LLC	25MG	N011722	002	Apr CAHN
	AA	+		25MG	N011722	002	Mar CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		TENUATE DOSPAN					
>A>	AB	+	ACTAVIS LABS UT INC	75MG	N012546	001	Apr CAHN
>D>	AB	+	ALLERGAN SALES LLC	75MG	N012546	001	Apr CAHN
	AB	+		75MG	N012546	001	Mar CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

>D>	AP	BEDFORD LABS	1MG/ML	A040453	001	Jun 09, 2003	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003	Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

@ ACTAVIS LABS FL INC 120MG

A074852 001 Oct 10, 1997 Jan DISC

@ 180MG

A074852 002 Oct 10, 1997 Jan DISC

@ 240MG

A074852 003 Oct 10, 1997 Jan DISC

AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

>D>	AP	+	BEDFORD	5MG/ML	A074617	001	Feb 28, 1996	Apr CAHN
>A>	AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

		+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan CAHN
--	--	---	--------------------	------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

@	HIKMA PHARMS	50MG	A083567	001			Feb CAHN
@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987		Mar CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE

>D>	AP	+	BEDFORD	5MG/ML	A074939	001	Apr 13, 1998	Apr CAHN
>A>	AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL
DISOPYRAMIDE PHOSPHATE

@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985		Feb CAHN
@		EQ 150MG BASE	A070471	001	Dec 10, 1985		Feb CAHN
@	SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985		Mar CAHN
@		EQ 150MG BASE	A070352	001	Dec 17, 1985		Mar CAHN

DISULFIRAM

TABLET;ORAL
DISULFIRAM

AB			ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan CAHN
----	--	--	---------------	-------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

@	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009		Feb DISC
@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009		Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

@	TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995		Jan CAHN
---	---------------------	-------------------	---------	-----	--------------	--	----------

DOCETAXEL

SOLUTION;IV (INFUSION)
DOCETAXEL

EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015		Jan CAHN
	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015		Jan CAHN
	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015		Jan CAHN

DOLASETRON MESYLATE

INJECTABLE;INJECTION
ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997		Jan CAHN
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997		Jan CAHN
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001		Jan CAHN

TABLET;ORAL
ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997		Jan CAHN
+		100MG	N020623	002	Sep 11, 1997		Jan CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016		Feb NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016		Mar NEWA
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016		Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar CAHN
@	10MG	A077975	001	Dec 11, 2009	Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION
DOXAPRAM HYDROCHLORIDE

>D> AP	BEDFORD	20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN
>A> AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@ IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@	EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@	EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@	EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@ SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@	EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@	EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@	EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

>A>	+ AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr NEWA
-----	---------------	--------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar CAHN
----	----------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar DISC	
AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar CAHN
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar CAHN
@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar DISC	

TABLET, DELAYED RELEASE;ORAL

DORYX

>D>	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr CFTG
>A> AB		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr CFTG

DOXYCYCLINE HYCLATE

@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC	
@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC	
>A> AB	MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
MELAMISA

AB NOVAST LABS LTD 3MG;0.02MG A202016 001 Jan 26, 2016 Jan NEWA
TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL
AB GLENMARK PHARMS LTD 3MG;0.03MG A204848 001 Mar 25, 2016 Mar NEWA

DUTASTERIDE

CAPSULE; ORAL
DUTASTERIDE

>A> AB AUROLIFE PHARMA LLC 0.5MG A202660 001 Nov 20, 2015 Apr CAHN
AB BIONPHARMA INC 0.5MG A200899 001 Nov 20, 2015 Jan CAHN
AB INTERGEL PHARMS INC 0.5MG A206373 001 Mar 17, 2016 Feb NEWA
>D> AB SANDOZ INC 0.5MG A202660 001 Nov 20, 2015 Apr CAHN
AB STRIDES PHARMA 0.5MG A204262 001 Nov 20, 2015 Mar CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
TENSILON

@ TELIGENT PHARMA INC 10MG/ML N007959 001 Jan CAHN

TENSILON PRESERVATIVE FREE
@ TELIGENT PHARMA INC 10MG/ML N007959 002 Jan CAHN

EFAVIRENZ

TABLET; ORAL
EFAVIRENZ

AB MYLAN LABS LTD 600MG A091471 001 Feb 17, 2016 Feb NEWA

SUSTIVA
AB + BRISTOL MYERS SQUIBB 600MG N021360 002 Feb 01, 2002 Feb CFTG

ELBASVIR; GRAZOPREVR

TABLET; ORAL
ZEPATIER

+ MERCK SHARP DOHME 50MG;100MG N208261 001 Jan 28, 2016 Jan NEWA

>A> EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

>A> TABLET; ORAL

>A> ODEFSEY

>A> + GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Apr CAIN

>D> EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

>D> TABLET; ORAL

>D> ODEFSEY

>D> + GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Apr CAIN

+ 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Mar NEWA

>A> EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

>A> TABLET; ORAL

>A> DESCOVY

>A> + GILEAD SCIENCES INC 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 Apr NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

GILEAD 100MG;150MG N021752 002 Mar 10, 2016 Mar NEWA

133MG;200MG N021752 003 Mar 10, 2016 Mar NEWA

167MG;250MG N021752 004 Mar 10, 2016 Mar NEWA

ENALAPRILAT

INJECTABLE; INJECTION
ENALAPRILAT

>D> AP + BEDFORD 1.25MG/ML A075634 001 Aug 22, 2000 Apr CAHN

>A> AP + EUROHLTH INTL SARL 1.25MG/ML A075634 001 Aug 22, 2000 Apr CAHN

>A>	<u>EPHEDRINE SULFATE</u>				
>A>	SOLUTION;INTRAVENOUS				
>A>	AKOVAZ				
>A>	+	FLAMEL IRELAND LTD	50MG/ML	N208289 001	Apr 29, 2016 Apr NEWA
<u>EPINASTINE HYDROCHLORIDE</u>					
SOLUTION/DROPS;OPHTHALMIC					
EPINASTINE HYDROCHLORIDE					
AT		SOMERSET THERAPS LLC	0.05%	A090951 001	Oct 31, 2011 Mar CAHN
<u>EPINEPHRINE</u>					
INJECTABLE;INJECTION					
SUS-PHRINE SULFITE FREE					
@ FOREST LABS 1.5MG/AMP					
@ 5MG/ML					
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS					
AUVI-Q					
BX	+	KALEO INC	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012 Mar CAHN
BX			EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012 Mar CAHN
<u>EPINEPHRINE HYDROCHLORIDE</u>					
SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
EPINEPHRINE					
		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029 001	Jul 29, 2014 Feb CDFR
<u>ERGOCALCIFEROL</u>					
CAPSULE;ORAL					
DRISDOL					
AA	+	US PHARM HOLDINGS	50,000 IU	N003444 001	Jan CAHN
VITAMIN D					
AA		BIONPHARMA INC	50,000 IU	A080704 001	Jan CAHN
<u>ERGOLOID MESYLATES</u>					
TABLET;ORAL					
ERGOLOID MESYLATES					
AB		SUN PHARM INDS	1MG	A081113 001	Oct 31, 1991 Mar CAHN
<u>ERYTHROMYCIN</u>					
SOLUTION;TOPICAL					
C-SOLVE-2					
@ FOUGERA PHARMS 2%					
ERYTHRO-STATIN					
@ HI TECH PHARMA 2%					
ERYTHROMYCIN					
AT	+	FOUGERA PHARMS	2%	A064187 001	Sep 30, 1997 Jan CRLD
AT		PERRIGO NEW YORK	2%	A063038 001	Jan 11, 1991 Jan CRLD
<u>ESCITALOPRAM OXALATE</u>					
SOLUTION;ORAL					
ESCITALOPRAM OXALATE					
AA		MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754 001	Mar 31, 2016 Mar NEWA
<u>ESMOLOL HYDROCHLORIDE</u>					
>A>	SOLUTION;INTRAVENOUS				
>A>	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER				
>A>	+	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703 002	Apr 07, 2016 Apr NEWA
>A>	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER				
>A>		HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703 001	Apr 07, 2016 Apr NEWA
<u>ESOMEPRAZOLE MAGNESIUM</u>					
CAPSULE, DELAYED REL PELLETS;ORAL					
ESOMEPRAZOLE MAGNESIUM					
>A> AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606 001	Apr 21, 2016 Apr NEWA
>A> AB			EQ 40MG BASE	A205606 002	Apr 21, 2016 Apr NEWA
>D> AB		HETERO LABS LTD III	EQ 20MG BASE	A202784 001	Sep 21, 2015 Apr CTEC
>A> BX			EQ 20MG BASE	A202784 001	Sep 21, 2015 Apr CTEC
>D> AB			EQ 40MG BASE	A202784 002	Sep 21, 2015 Apr CTEC
>A> BX			EQ 40MG BASE	A202784 002	Sep 21, 2015 Apr CTEC

ESTRADIOL

CREAM;VAGINAL

ESTRACE

>A>	+	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr CAHN
>D>	+	WARNER CHILCOTT US	0.01%	A086069	001	Jan 31, 1984	Apr CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

		APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan CAHN
+			EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan CAHN

TABLET;ORAL

FEMTRACE

		APIL	0.45MG	N021633	001	Aug 20, 2004	Jan CAHN
			0.9MG	N021633	002	Aug 20, 2004	Jan CAHN
+			1.8MG	N021633	003	Aug 20, 2004	Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan NEWA
		ZOVIA 1/50E-28					
AB	+	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

AB		LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar NEWA
----	--	-----------	---	---------	-----	--------------	----------

QUARTETTE

AB	+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CFTG
----	---	--------------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

>D>		@ ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566	001		Apr CAHN
>A>		@ ALLERGAN SALES LLC	0.035MG;0.5MG	N017566	001		Apr CAHN

NORINYL 1+35 21-DAY

AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar CAHN
----	--	--------------------	-------------	---------	-----	--	----------

TABLET;ORAL-28

BREVICON 28-DAY

AB		ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar CAHN
----	--	--------------------	---------------	---------	-----	--	----------

NORINYL 1+35 28-DAY

AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar CAHN
----	--	--------------------	-------------	---------	-----	--	----------

TABLET, CHEWABLE;ORAL

FEMCON FE

AB	+	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
----	---	------	---------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
----	---	------	---------------	---------	-----	--------------	----------

AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar NEWA
----	--	-----------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A>		@ APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr CAHN
>D>		@ WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr CAHN

TABLET;ORAL

FEMHRT

AB		APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
		@	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan CAHN

LO LOESTRIN FE

+		APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan CAHN
---	--	------	-----------------------	---------	-----	--------------	----------

		TABLET;ORAL-21					
		ESTROSTEP 21					
		@ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan CAHN
		LOESTRIN 21 1.5/30					
>A>	AB	APIL	0.03MG;1.5MG	N017875	001		Apr CAHN
>D>	AB	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		Apr CAHN
		LOESTRIN 21 1/20					
>A>	AB	APIL	0.02MG;1MG	N017876	001		Apr CAHN
>D>	AB	WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		Apr CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan NEWA
		TABLET;ORAL-28					
		ESTROSTEP FE					
	AB	+ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan CAHN
		LOESTRIN FE 1.5/30					
>A>	AB	+ APIL	0.03MG;1.5MG	N017355	001		Apr CAHN
>D>	AB	+ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		Apr CAHN
		LOESTRIN FE 1/20					
>A>	AB	APIL	0.02MG;1MG	N017354	001		Apr CAHN
>D>	AB	WARNER CHILCOTT	0.02MG;1MG	N017354	001		Apr CAHN
		TABLET, CHEWABLE;ORAL					
		MINASTRIN 24 FE					
		+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	Jan CAHN
		TABLET, CHEWABLE, TABLET;ORAL					
		LO MINASTRIN FE					
		+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan CAHN
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>							
		TABLET;ORAL-28					
		NORGESTIMATE AND ETHINYL ESTRADIOL					
	AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Feb NEWA
	AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	Jan NEWA
	AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan NEWA
>A>	AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205588	001	Apr 26, 2016	Apr NEWA
<u>ETHOSUXIMIDE</u>							
		CAPSULE;ORAL					
		ETHOSUXIMIDE					
	AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan CAHN
<u>ETIDRONATE DISODIUM</u>							
		TABLET;ORAL					
		DIDRONEL					
>A>	AB	APIL	200MG	N017831	001		Apr CAHN
>A>	AB	+	400MG	N017831	002		Apr CAHN
>D>	AB	PROCTER AND GAMBLE	200MG	N017831	001		Apr CAHN
>D>	AB	+	400MG	N017831	002		Apr CAHN
<u>ETODOLAC</u>							
		CAPSULE;ORAL					
		ETODOLAC					
		@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb CAHN
<u>ETOMIDATE</u>							
		INJECTABLE;INJECTION					
		ETOMIDATE					
>D>	AP	BEDFORD	2MG/ML	A074593	001	Nov 04, 1996	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr CAHN
	AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb NEWA
<u>EXEMESTANE</u>							
		TABLET;ORAL					
		EXEMESTANE					
	AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN

+ ASTRAZENECA AB 2MG N022200 002 Feb 28, 2014 Feb NEWA

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE

>D>	AP	BEDFORD	10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
>D>	AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
>A>	AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN
		FAMOTIDINE PRESERVATIVE FREE					
>D>	AP	BEDFORD	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
>D>	AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
>A>	AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET;ORAL

FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

>A>	AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA
>A>	AB		145MG	A205118	002	May 05, 2016	Apr NEWA

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

>A>		ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
>A>	+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
>D>		TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Apr CAHN
>D>	+		105MG	N022418	002	Aug 14, 2009	Apr CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
@	SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA
----	-------	------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

>A>	+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr NEWA
-----	---	----------------------	-------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
@		8MG	A204827	002	Dec 10, 2015	Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar DISC
@ IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar DISC

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar DISC
----------------	-------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
@	200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

>D>	BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr CAHN
>D> AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr CAHN
>D> AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr CAHN
>A>	EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr CAHN
>A> AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr CAHN
>A> AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr CAHN
	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan DISC
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CMS1

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

>D> AP	BEDFORD LABS	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
>D> AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN
>A> AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
>A> AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

>A> AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
>A> AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

>A> AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
--------	------	-------	---------	-----	--------------	----------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

@ SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar CAHN
@	EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD
---	---------------------	--------------	---------	-----	--------------	----------

TABLET; ORAL

SARAFEM

AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

AT	+	AQUA PHARMS	0.05%	N012806	002		Mar CFTG
		FLURANDRENOLIDE					

AT		TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

TAPE; TOPICAL

CORDRAN

>D>	+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Apr CAHN
>A>	+	ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr CAHN

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN N

@ LILLY

0.05%;EQ 3.5MG BASE/GM

N050346	001		Mar CMS1
---------	-----	--	----------

OINTMENT; TOPICAL

CORDRAN N

@ LILLY

0.05%;EQ 3.5MG BASE/GM

N050345	001		Mar CMS1
---------	-----	--	----------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC

15MG

A071716	001	Jul 31, 1991	Feb CAHN
---------	-----	--------------	----------

@

30MG

A071717	001	Jul 31, 1991	Feb CAHN
---------	-----	--------------	----------

@ SUN PHARM INDS

15MG

A070454	001	Aug 04, 1986	Mar CAHN
---------	-----	--------------	----------

@

30MG

A070455	001	Aug 04, 1986	Mar CAHN
---------	-----	--------------	----------

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@ AUROLIFE PHARMA LLC

50MG

A074448	001	Jul 28, 1995	Feb CAHN
---------	-----	--------------	----------

@

100MG

A074448	002	Jul 28, 1995	Feb CAHN
---------	-----	--------------	----------

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+	GLAXOSMITHKLINE	0.1MG/INH
---	-----------------	-----------

N205625	001	Aug 20, 2014	Mar CRLD
---------	-----	--------------	----------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH
---	---------------	-------------------------------

N204275	002	Apr 30, 2015	Mar CRLD
---------	-----	--------------	----------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ NOSTRUM LABS INC

25MG

A075900	001	Feb 23, 2006	Feb CAHN
---------	-----	--------------	----------

@

50MG

A075900	002	Feb 23, 2006	Feb CAHN
---------	-----	--------------	----------

@

100MG

A075900	003	Feb 23, 2006	Feb CAHN
---------	-----	--------------	----------

@ SUN PHARM INDS

25MG

A076125	001	Apr 29, 2002	Mar CAHN
---------	-----	--------------	----------

@

50MG

A076125	002	Apr 29, 2002	Mar CAHN
---------	-----	--------------	----------

@

100MG

A076125	003	Apr 29, 2002	Mar CAHN
---------	-----	--------------	----------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

@ SUN PHARM INDS

1MG

A040582	001	Jul 18, 2005	Mar CAHN
---------	-----	--------------	----------

>A> FORMOTEROL FUMARATE; GLYCOPYRROLATE

>A> AEROSOL, METERED; INHALATION

>A> BEVESPI AEROSPHERE

>A>	+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Apr NEWA
-----	---	-------------------	---------------------------	---------	-----	--------------	----------

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

>A> FOSAMPRENAVIR CALCIUM

>A> AB	MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr NEWA
	LEXIVA					

>D>	+	VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr CFTG
>A> AB	+		EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr CFTG

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
@		20MG	A076620	002	Oct 15, 2004	Jan DISC
@		40MG	A076620	003	Oct 15, 2004	Jan DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

@	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
@	LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb DISC

TABLET;ORAL

FUROSEMIDE

@	SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
@		80MG	A070100	001	Jan 26, 1988	Mar CAHN

LASIX

AB	US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
AB		40MG	N016273	001		Jan CAHN
AB	+	80MG	N016273	003		Jan CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
AB		300MG	A204989	002	Feb 18, 2016	Feb NEWA
AB		400MG	A204989	003	Feb 18, 2016	Feb NEWA
	@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar CAHN
	@	300MG	A076537	002	Jun 30, 2005	Mar CAHN
	@	400MG	A076537	003	Jun 30, 2005	Mar CAHN

SOLUTION;ORAL

GABAPENTIN

AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

GABAPENTIN

AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB		800MG	A205101	002	Feb 04, 2016	Jan NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

@	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb DISC
@		EQ 16MG BASE	A078484	002	May 27, 2009	Feb DISC
@		EQ 24MG BASE	A078484	003	May 27, 2009	Feb DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar	NEWA
AP			1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar	NEWA
AP			2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar	NEWA
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar	CFTG
AP	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar	CFTG
AP	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar	CFTG

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

	@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan	DISC
	@		2MG	A076995	002	Apr 27, 2010	Jan	DISC
	@		4MG	A076995	003	Apr 27, 2010	Jan	DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar	NEWA
		2MG; 4MG	A078709	002	Apr 01, 2016	Mar	NEWA
		2MG; 8MG	A078709	004	Apr 01, 2016	Mar	NEWA
		4MG; 4MG	A078709	003	Apr 01, 2016	Mar	NEWA
		4MG; 8MG	A078709	005	Apr 01, 2016	Mar	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>A>	AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr	NEWA
>A>	AB1		2.5MG	A203581	002	Apr 14, 2016	Apr	NEWA
>A>	AB1		5MG	A203581	003	Apr 14, 2016	Apr	NEWA
>A>	AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr	NEWA
>A>	AB1		2.5mg	A206749	002	May 10, 2016	Apr	NEWA
>A>	AB1		5MG	A206749	003	May 10, 2016	Apr	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

	@	COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan	DISC
	@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan	DISC
	@		5MG; 500MG	A076731	003	Nov 19, 2004	Jan	DISC
AB		ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb	NEWA
AB			2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb	NEWA
AB			5MG; 500MG	A206748	003	Feb 29, 2016	Feb	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb	CRLD
		ROBINUL						
	@	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb	DISC

TABLET; ORAL

GLYCOPYRROLATE

AA		RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan	CAHN
AA			2MG	A040821	002	Dec 29, 2008	Jan	CAHN
		ROBINUL						
AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan	CAHN
		ROBINUL FORTE						
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan	CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan	CMS1
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

@ COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
--------------	-------------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

>D>	+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
>A>	+	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

@ IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
@	EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
@	EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
@	EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

@ CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
@ SUN PHARM INDS	2MG	A071172	001	Jan 02, 1987	Mar CAHN
@	5MG	A071212	001	Jan 07, 1988	Mar CAHN
@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
@	20MG	A071177	001	Jan 07, 1988	Mar CAHN
@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@ ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000	Jan CMS1
---------------------	-----------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

>A> AP		MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
--------	--	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>D> AA		ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
>A>	@		10MG	A091679	001	Mar 04, 2013	Apr DISC
>D> AA			25MG	A091679	002	Mar 04, 2013	Apr DISC
>A>	@		25MG	A091679	002	Mar 04, 2013	Apr DISC
>D> AA			50MG	A091679	003	Mar 04, 2013	Apr DISC
>A>	@		50MG	A091679	003	Mar 04, 2013	Apr DISC
>D> AA			100MG	A091679	004	Mar 04, 2013	Apr DISC
>A>	@		100MG	A091679	004	Mar 04, 2013	Apr DISC
	@ SUN PHARM INDS		10MG	A089359	001	Jul 25, 1986	Mar CAHN
	@		25MG	A089258	001	May 05, 1986	Mar CAHN
	@		50MG	A089259	001	May 05, 1986	Mar CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	25MG;15MG	A085827	001		Feb CMS1
---------------	-----------	---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar CAHN
------------------	-----------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

MICROZIDE

>D> AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
>A> AB	+	ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb CAHN
@	50MG	A085219	001		Feb CAHN
@ SUN PHARM INDS	25MG	A083972	001		Mar CAHN
@	50MG	A083972	002		Mar CAHN
@	100MG	A083972	003		Mar CAHN
ORETIC					
@ ABBVIE	50MG	N011971	002		Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar NEWA
AB INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan NEWA
AB	12.5MG;300MG	A203036	002	Jan 15, 2016	Jan NEWA
AB	25MG;300MG	A203036	003	Jan 15, 2016	Mar CTEC
	25MG;300MG	A203036	003	Jan 15, 2016	Jan NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

ZESTORETIC

AB ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB +	12.5MG;20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB +	25MG;20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar CAHN
-------------------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan NEWA
AB	12.5MG;160MG	A206083	002	Feb 08, 2016	Jan NEWA
AB	12.5MG;320MG	A206083	003	Feb 08, 2016	Jan NEWA
AB	25MG;160MG	A206083	004	Feb 08, 2016	Jan NEWA
AB	25MG;320MG	A206083	005	Feb 08, 2016	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

@ ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan DISC
-----------------------	-----------	---------	-----	--------------	----------

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

>A> AB PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr NEWA
>A> AB	10MG	A207029	002	Apr 26, 2016	Apr NEWA
>A> AB	20MG	A207029	003	Apr 26, 2016	Apr NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

PEDIOTIC

@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan DISC
------------------	-------------------------------------	---------	-----	--------------	----------

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan CAHN
+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb CMFD
----------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

+	ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015	Jan CAHN
SOLUTION; INTRAMUSCULAR						
MAKENA						
+	LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@	AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982	Feb CAHN
@		25MG	A087870	001	Dec 20, 1982	Feb CAHN
@		50MG	A087871	001	Dec 20, 1982	Feb CAHN
@	SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar CAHN
@		25MG	A089382	001	May 19, 1986	Mar CAHN
@		50MG	A089383	001	May 19, 1986	Mar CAHN
@		100MG	A087862	001	Apr 18, 1983	Mar CAHN

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan NEWA
----	-----------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

IBANDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar CAHN

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@	AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986	Feb CAHN
@		400MG	A070735	001	Jun 12, 1986	Feb CAHN
@		600MG	A070736	001	Jun 12, 1986	Feb CAHN
@		800MG	A071938	001	Jan 14, 1988	Mar CAHN
@	SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar CAHN
@		600MG	A070080	001	Jul 24, 1985	Mar CAHN
@		800MG	A071448	001	Feb 18, 1987	Mar CAHN

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYSINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
NEOPROFEN						

AP	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG
----	---	----------------	------------------------------------	---------	-----	--------------	----------

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar CAHN
AB		25MG	A081049	001	Jun 05, 1990	Mar CAHN
AB		50MG	A081050	001	Jun 05, 1990	Mar CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb CRLD
TOFRANIL-PM							
@		MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb DISC
@			EQ 100MG HCL	N017090	004		Feb DISC
@			EQ 125MG HCL	N017090	003		Feb DISC
@			EQ 150MG HCL	N017090	002		Feb DISC

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
---	---------------------	------------	---------	-----	--------------	----------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

+ GE HEALTHCARE 1mCi/ML N019044 001 Dec 24, 1985 Mar CMS1

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
OCTREOSCAN

+ MALLINKRODT NUCLEAR 3mCi/ML N020314 001 Jun 02, 1994 Jan CAHN

INDOCYANINE GREEN

INJECTABLE;INJECTION
INDOCYANINE GREEN

AP DIAGNOSTIC GREEN 25MG/VIAL A040811 001 Nov 21, 2007 Jan CAHN

INDOMETHACIN SODIUM

INJECTABLE;INJECTION
INDOMETHACIN SODIUM

>A> AP HOSPIRA INC EQ 1MG BASE/VIAL A204118 001 Apr 19, 2016 Apr NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 002 Jun 16, 2005 Feb DISC

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS
HUMULIN R

+ LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994 Jan CAIN

HUMULIN R KWIKPEN

+ LILLY 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015 Jan NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION
AFREZZA

+ MANNKIND 4 UNITS/INH N022472 001 Jun 27, 2014 Mar CAHN

8 UNITS/INH N022472 002 Jun 27, 2014 Mar CAHN

12 UNITS/INH N022472 003 Apr 17, 2015 Mar CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION
CAMPOTOSAR

>D> + PFIZER INC 300MG/15ML (20MG/ML) N020571 003 Aug 05, 2010 Apr CTEC

>A> AP + 300MG/15ML (20MG/ML) N020571 003 Aug 05, 2010 Apr CTEC

IRINOTECAN HYDROCHLORIDE

>A> AP QILU PHARM CO LTD 40MG/2ML (20MG/ML) A203380 001 May 03, 2016 Apr NEWA

>A> AP 100MG/5ML (20MG/ML) A203380 002 May 03, 2016 Apr NEWA

>A> AP 300MG/15ML (20MG/ML) A203380 003 May 03, 2016 Apr NEWA

AP SANDOZ INC 40MG/2ML (20MG/ML) A090137 001 Nov 12, 2009 Jan CAHN

AP 100MG/5ML (20MG/ML) A090137 002 Nov 12, 2009 Jan CAHN

IRON DEXTRAN

INJECTABLE;INJECTION
INFED

>D> BP + ACTAVIS LABS UT INC EQ 50MG IRON/ML N017441 001 Apr CAHN

>A> BP + ALLERGAN SALES LLC EQ 50MG IRON/ML N017441 001 Apr CAHN

ISONIAZID

TABLET;ORAL
ISONIAZID

@ SUN PHARM INDS 100MG A080136 001 Mar CAHN

@ 300MG A083633 001 Mar CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE;ORAL
DILATRATE-SR

+ AUXILIUM PHARMS INC 40MG N019790 001 Sep 02, 1988 Mar CAHN

TABLET;ORAL

ISOSORBIDE DINITRATE

@ SUN PHARM INDS 5MG A086166 002 Sep 19, 1986 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@ COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar DISC
+ SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar CTEC

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan NEWA
AP	+ MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan CTEC

ITRACONAZOLE

SOLUTION;ORAL

>D>	ITRACONAZOLE					
>D> AA	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Apr DISC
>A>	@	10MG/ML	A205573	001	Oct 30, 2015	Apr DISC
	SPORANOX					
>D> AA	+ JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Apr CTEC
>A>	+	10MG/ML	N020657	001	Feb 21, 1997	Apr CTEC

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

@ SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan CAHN
------------------	-------	---------	-----	--------------	----------

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

@ AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb CAHN
@	75MG	A074024	002	Dec 29, 1995	Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

>D>	@ BEDFORD	15MG/ML	A075222	001	Apr 26, 1999	Apr CAHN
>D>	@	30MG/ML	A075222	002	Apr 26, 1999	Apr CAHN
>A>	@ EUROHLTH INTL SARL	15MG/ML	A075222	001	Apr 26, 1999	Apr CAHN
>A>	@	30MG/ML	A075222	002	Apr 26, 1999	Apr CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan CTNA
	TRANDATE					
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan CAHN

LACOSAMIDE

SOLUTION;ORAL

LACOSAMIDE

>A> AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr NEWA
	VIMPAT					
>D>	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr CFTG
>A> AA	+	10MG/ML	N022255	001	Apr 20, 2010	Apr CFTG

TABLET;ORAL

LACOSAMIDE

>A> AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr NEWA
>A> AB		100MG	A204855	002	Apr 28, 2016	Apr NEWA
>A> AB		150MG	A204855	003	Apr 28, 2016	Apr NEWA
>A> AB		200MG	A204855	004	Apr 28, 2016	Apr NEWA
>A> AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr NEWA
>A> AB		100MG	A204974	002	Apr 28, 2016	Apr NEWA
>A> AB		150MG	A204974	003	Apr 28, 2016	Apr NEWA
>A> AB		200MG	A204974	004	Apr 28, 2016	Apr NEWA
>A> AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr NEWA
>A> AB		100MG	A204994	002	Apr 28, 2016	Apr NEWA
>A> AB		150MG	A204994	003	Apr 28, 2016	Apr NEWA
>A> AB		200MG	A204994	004	Apr 28, 2016	Apr NEWA

TABLET;ORAL

LACOSAMIDE

>A>	AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr NEWA
>A>	AB		100MG	A204921	002	Apr 28, 2016	Apr NEWA
>A>	AB		150MG	A204921	003	Apr 28, 2016	Apr NEWA
>A>	AB		200MG	A204921	004	Apr 28, 2016	Apr NEWA
>A>	AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr NEWA
>A>	AB		100MG	A205026	002	Apr 28, 2016	Apr NEWA
>A>	AB		150MG	A205026	003	Apr 28, 2016	Apr NEWA
>A>	AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
>A>	AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
>A>	AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
>A>	AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
>A>	AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA
VIMPAT							
>D>		UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
>A>	AB		50MG	N022253	001	Oct 28, 2008	Apr CFTG
>D>			100MG	N022253	002	Oct 28, 2008	Apr CFTG
>A>	AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
>D>			150MG	N022253	003	Oct 28, 2008	Apr CFTG
>A>	AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
>D>	+		200MG	N022253	004	Oct 28, 2008	Apr CFTG
>A>	AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB		MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb NEWA
AB			300MG	A204528	002	Mar 04, 2016	Feb NEWA

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan CRLD
----	---	---------------------	-------	---------	-----	--------------	----------

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

>A>	AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr NEWA
-----	----	---------	--------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL

LETROZOLE

AB		KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan CAHN
----	--	----------------------	-------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
AN			EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
AN			EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP		AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
----	--	----------------------	----------------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB		INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB			750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB		SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB			750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION;ORAL

SPRITAM

		APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb CDFFR
			500MG	N207958	002	Jul 31, 2015	Feb CDFFR
			750MG	N207958	003	Jul 31, 2015	Feb CDFFR
	+		1GM	N207958	004	Jul 31, 2015	Mar CRLD
			1GM	N207958	004	Jul 31, 2015	Feb CDFFR

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+ RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan CAHN
----	---------------------	------	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D>	AB	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD
>A>		+	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD
>D>	AB	+ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr DISC
>A>		@	0.75MG	A078665	001	Aug 28, 2009	Apr DISC
>D>		PLAN B					
>D>	AB	+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr DISC
>A>		@	0.75MG	N021045	002	Aug 24, 2006	Apr DISC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA
----	---------------------	----	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	400MG/100ML	N018388	002		Feb DISC
---	---------	-------------	---------	-----	--	----------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982	Feb DISC
---	---------	-------------	---------	-----	--------------	----------

JELLY;TOPICAL

ANESTACON

@	BIONPHARMA INC	2%	A080429	001		Jan CAHN
---	----------------	----	---------	-----	--	----------

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

TABLET;ORAL

LINEZOLID

AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan NEWA
AB	GLENMARK PHARMS	600MG	A078987	001	Dec 21, 2015	Mar CAHN

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE	A090097	001	Mar 20, 2009	Mar CAHN	
AB		EQ 0.025MG BASE	A090097	002	Mar 20, 2009	Mar CAHN	
AB		EQ 0.05MG BASE	A090097	003	Mar 20, 2009	Mar CAHN	
>A>	AB	SUN PHARM INDS LTD	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Apr NEWA
>A>	AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Apr NEWA
>A>	AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Apr NEWA

LISINOPRIL

TABLET;ORAL

ZESTRIL

AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan CAHN
AB		5MG	N019777	001	May 19, 1988	Jan CAHN
AB		10MG	N019777	002	May 19, 1988	Jan CAHN
AB		20MG	N019777	003	May 19, 1988	Jan CAHN
AB		30MG	N019777	006	Jan 20, 1999	Jan CAHN
AB	+	40MG	N019777	004	May 19, 1988	Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb CAHN
AB		300MG	A076243	001	Jun 27, 2002	Feb CAHN
AB		600MG	A078763	001	Apr 15, 2008	Feb CAHN
AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan CMFD

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CRLD
+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

@ J AND J CONSUMER INC 2MG

LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	2MG	A072741	001	Sep 18, 1991	Feb CRLD
----	---	-------	-----	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>D>	AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr CTEC
>A>	BX		25MG	A203835	001	Aug 12, 2015	Apr CTEC
>D>	AB		50MG	A203835	002	Aug 12, 2015	Apr CTEC
>A>	BX		50MG	A203835	002	Aug 12, 2015	Apr CTEC
>D>	AB		100MG	A203835	003	Aug 12, 2015	Apr CTEC
>A>	BX		100MG	A203835	003	Aug 12, 2015	Apr CTEC
>D>	AB	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr CTEC
>A>	BX		25MG	A078232	001	Oct 06, 2010	Apr CTEC
>D>	AB		50MG	A078232	002	Oct 06, 2010	Apr CTEC
>A>	BX		50MG	A078232	002	Oct 06, 2010	Apr CTEC
>D>	AB		100MG	A078232	003	Oct 06, 2010	Apr CTEC
>A>	BX		100MG	A078232	003	Oct 06, 2010	Apr CTEC

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINE

POWDER;INHALATION

ADASUVE

+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN
---	---------------	------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA	
AP	+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA	

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@ RISING PHARMS INC

12.5MG

A040179 001 Jan 30, 1997 Jan CAHN

@

25MG

A040179 002 Jan 30, 1997 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB + ENDO PHARMS INC

125MG/ML

N021778 001 Jul 05, 2005 Feb CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@ SUN PHARM INDS

7.5MG

A077935 001 Jul 19, 2006 Jan CAHN

@

15MG

A077935 002 Jul 19, 2006 Jan CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+ APOTEX INC

2MG

N014691 002 Jan CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP + APOTEX INC

EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 Jan CAHN

POWDER; IV (INFUSION)

EVOMELA

SPECTRUM PHARMS

EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016 Mar NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@ US PHARM HOLDINGS

25MG/ML

N005010 007 Jan CAHN

@

50MG/ML

N005010 002 Jan CAHN

@

75MG/ML

N005010 009 Jan CAHN

@

100MG/ML

N005010 003 Jan CAHN

SYRUP; ORAL

DEMEROL

@ US PHARM HOLDINGS

50MG/5ML

N005010 005 Jan CAHN

TABLET; ORAL

DEMEROL

AA + US PHARM HOLDINGS

50MG

N005010 001 Jan CAHN

AA

+

100MG

N005010 004 Jan CAHN

MEPERIDINE HYDROCHLORIDE

@ SUN PHARM INDS

50MG

A080448 001 Mar CAHN

@

100MG

A080448 002 Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ AUROLIFE PHARMA LLC

400MG

A080655 001 Feb CAHN

@ SUN PHARM INDS

200MG

A080699 001 Mar CAHN

@

400MG

A080699 002 Mar CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

>A> AB DR REDDYS LABS INTL

50MG

A040461 001 Feb 11, 2004 Apr CAHN

>D> AB PROMETHEUS LABS

50MG

A040461 001 Feb 11, 2004 Apr CAHN

PURINETHOL

@ STASON PHARMS

50MG

N009053 002 Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP AMNEAL PHARMS

500MG/VIAL

A205883 001 Apr 12, 2016 Mar NEWA

AP

+

1GM/VIAL

A205883 002 Apr 12, 2016 Mar NEWA

>A> AP SAVIOR LIFETEC CORP

500MG/VIAL

A206086 001 Apr 19, 2016 Apr NEWA

>A> AP

+

1GM/VIAL

A206086 002 Apr 19, 2016 Apr NEWA

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL

+ APIL 400MG

N204412 001 Feb 01, 2013 Jan CAHN

TABLET, DELAYED RELEASE;ORAL
ASACOL

@ APIL 400MG

N019651 001 Jan 31, 1992 Jan CAHN

ASACOL HD

+ APIL 800MG

N021830 001 May 29, 2008 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB SUN PHARM INDS 500MG

A076038 001 Feb 21, 2002 Mar CAHN

AB 850MG

A076038 002 Feb 21, 2002 Mar CAHN

AB 1GM

A076038 003 Feb 21, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
GLUMETZA

AB3 SANTARUS INC 500MG

N021748 001 Jun 03, 2005 Jan CTEC

AB3 + 1GM

N021748 002 Jun 03, 2005 Jan CTEC

METFORMIN HYDROCHLORIDE

@ IMPAX LABS 500MG

A076249 001 Jul 30, 2004 Mar DISC

@ 750MG

A076985 001 Sep 13, 2005 Mar DISC

>A> AB1 MARKSANS PHARMA 500MG

A090295 001 Apr 29, 2016 Apr NEWA

>A> AB 750MG

A090295 002 Apr 29, 2016 Apr NEWA

@ SUN PHARM INDS 500MG

A077124 001 Dec 21, 2005 Mar CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB + US PHARM HOLDINGS 1GM

N017681 001 Jan CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB RISING PHARMS INC 5MG

A202068 001 Mar 07, 2012 Jan CAHN

AB 10MG

A202068 002 Mar 07, 2012 Jan CAHN

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

@ SANDOZ 500MG

A084616 001 Feb DISC

@ 750MG

A084615 001 Feb DISC

@ SUN PHARM INDS 500MG

A084488 001 Mar CAHN

@ 750MG

A084486 001 Mar CAHN

ROBAXIN

AA + AUXILIUM PHARMS INC 500MG

N011011 004 Mar CAHN

ROBAXIN-750

AA + AUXILIUM PHARMS INC 750MG

N011011 006 Mar CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP SANDOZ INC EQ 50MG BASE/2ML (EQ 25MG BASE/ML)

A090039 001 Mar 31, 2009 Jan CAHN

AP EQ 250MG BASE/10ML (EQ 25MG
BASE/ML)

A090039 002 Mar 31, 2009 Jan CAHN

AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML)

A090029 001 Mar 31, 2009 Jan CAHN

METHOXSALEN

INJECTABLE;INJECTION

UVADEX

>A> + MALLINCKRODT HOSP 0.02MG/ML

N020969 001 Feb 25, 1999 Apr CAHN

>D> + THERAKOS 0.02MG/ML

N020969 001 Feb 25, 1999 Apr CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ SUN PHARM INDS 125MG

A070073 001 Oct 09, 1986 Mar CAHN

@ 250MG

A070060 001 Oct 09, 1986 Mar CAHN

@ 500MG

A070074 001 Oct 09, 1986 Mar CAHN

>A>	<u>METHYLENE BLUE</u>				
>A>	SOLUTION;INTRAVENOUS				
>A>	PROVAYBLUE				
>A>	+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630 001	Apr 08, 2016 Apr NEWA
<u>METHYLERGONOVINE MALEATE</u>					
TABLET;ORAL					
METHERGINE					
	@	EDISON THERAPS LLC	0.2MG	N006035 003	Jan DISC
METHYLERGONOVINE MALEATE					
	+	NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011 Jan CRLD
<u>METHYLPHENIDATE HYDROCHLORIDE</u>					
SOLUTION;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
AA		NOSTRUM LABS INC	5MG/5ML	A201466 001	Nov 12, 2013 Feb CAHN
AA			10MG/5ML	A201466 002	Nov 12, 2013 Feb CAHN
TABLET, EXTENDED RELEASE;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
AB		TEDOR PHARMA INC	10MG	A204772 001	Feb 29, 2016 Feb NEWA
AB			20MG	A204772 002	Feb 29, 2016 Feb NEWA
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>					
INJECTABLE;INJECTION					
METHYLPREDNISOLONE SODIUM SUCCINATE					
AP		HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691 001	Feb 16, 2016 Feb NEWA
AP			EQ 1GM BASE/VIAL	A202691 002	Feb 16, 2016 Feb NEWA
AP		SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888 001	Jul 18, 2011 Jan CAHN
AP			EQ 125MG BASE/VIAL	A040888 002	Jul 18, 2011 Jan CAHN
AP			EQ 500MG BASE/VIAL	A040888 003	Jul 18, 2011 Jan CAHN
AP			EQ 1GM BASE/VIAL	A040888 004	Jul 18, 2011 Jan CAHN
AP			EQ 2GM BASE/VIAL	A040888 005	Jul 18, 2011 Jan CAHN
<u>METHYLTESTOSTERONE</u>					
TABLET;ORAL					
>D>	ANDROID 10				
>D>	BP	VALEANT PHARM INTL	10MG	A086450 001	Apr DISC
>A>		@	10MG	A086450 001	Apr DISC
METHYLTESTOSTERONE					
		@ IMPAX LABS	25MG	A084310 001	Mar DISC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>					
TABLET;ORAL					
METOCLOPRAMIDE HYDROCHLORIDE					
AB		SUN PHARM INDS	EQ 5MG BASE	A071536 002	Jan 16, 1997 Mar CAHN
		@	EQ 10MG BASE	A071536 001	Apr 28, 1993 Mar CAHN
<u>METOPROLOL TARTRATE</u>					
INJECTABLE;INJECTION					
METOPROLOL TARTRATE					
>D>	AP	BEDFORD LABS	1MG/ML	A076495 001	Jul 07, 2003 Apr CAHN
>A>	AP	EUROHLTH INTL SARL	1MG/ML	A076495 001	Jul 07, 2003 Apr CAHN
TABLET;ORAL					
METOPROLOL TARTRATE					
AB		SUN PHARM INDS	25MG	A073654 002	Jul 15, 2009 Mar CAHN
AB			100MG	A073654 001	Dec 21, 1993 Mar CAHN
<u>METRONIDAZOLE</u>					
GEL;VAGINAL					
NUVESSA					
>D>	+	ACTAVIS LABS UT INC	1.3%	N205223 001	Mar 24, 2014 Apr CAHN
>A>	+	ALLERGAN SALES LLC	1.3%	N205223 001	Mar 24, 2014 Apr CAHN
TABLET;ORAL					
METRONIDAZOLE					
AB		NOSTRUM LABS INC	250MG	A070772 001	Jul 16, 1986 Jan CAHN
AB			500MG	A070773 001	Jul 16, 1986 Jan CAHN

MICONAZOLETABLET;BUCCAL
ORAVIG

+ MIDATECH PHARMA US 50MG N022404 001 Apr 16, 2010 Jan CAHN

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

>D>	AP	BEDFORD LABS	EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Apr CAHN
>D>	AP		EQ 5MG BASE/ML	A 075421	001	Jun 20, 2000	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Apr CAHN
>A>	AP		EQ 5MG BASE/ML	A 075421	001	Jun 20, 2000	Apr CAHN

MIGLITOLTABLET;ORAL
GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N 020682	001	Dec 18, 1996	Feb CRLD
AB			100MG	N 020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDETABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS	12.5MG	A 205081	001	Apr 22, 2016	Apr NEWA
>A>	AB		25MG	A 205081	002	Apr 22, 2016	Apr NEWA
>A>	AB		50MG	A 205081	003	Apr 22, 2016	Apr NEWA
>A>	AB		100MG	A 205081	004	Apr 22, 2016	Apr NEWA
		@ LIBERTY PHARMA INC	12.5MG	A 205071	001	Jan 27, 2016	Jan DISC
			12.5MG	A 205071	001	Jan 27, 2016	Jan NEWA
		@	25MG	A 205071	002	Jan 27, 2016	Jan DISC
			25MG	A 205071	002	Jan 27, 2016	Jan NEWA
		@	50MG	A 205071	003	Jan 27, 2016	Jan DISC
			50MG	A 205071	003	Jan 27, 2016	Jan NEWA
		@	100MG	A 205071	004	Jan 27, 2016	Jan DISC
			100MG	A 205071	004	Jan 27, 2016	Jan NEWA
		SAVELLA					
>D>		CYPRESS BIOSCIENCE	12.5MG	N 022256	001	Jan 14, 2009	Apr CFTG
>A>	AB		12.5MG	N 022256	001	Jan 14, 2009	Apr CFTG
>D>			25MG	N 022256	002	Jan 14, 2009	Apr CFTG
>A>	AB		25MG	N 022256	002	Jan 14, 2009	Apr CFTG
>D>	+		50MG	N 022256	003	Jan 14, 2009	Apr CFTG
>A>	AB	+	50MG	N 022256	003	Jan 14, 2009	Apr CFTG
>D>			100MG	N 022256	004	Jan 14, 2009	Apr CFTG
>A>	AB		100MG	N 022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATEINJECTABLE;INJECTION
MILRINONE LACTATE

>D>	AP	BEDFORD	EQ 1MG BASE/ML	A 075660	001	May 28, 2002	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A 075660	001	May 28, 2002	Apr CAHN
		MILRINONE LACTATE IN DEXTROSE 5%					
	AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 077151	002	Jul 20, 2005	Mar CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
		@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 077151	001	Jul 20, 2005	Mar CAHN

MINOCYCLINE HYDROCHLORIDETABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS	EQ 50MG BASE	A 090217	001	Jan 29, 2016	Jan NEWA
AB			EQ 75MG BASE	A 090217	002	Jan 29, 2016	Jan NEWA
AB			EQ 100MG BASE	A 090217	003	Jan 29, 2016	Jan NEWA
		TABLET, EXTENDED RELEASE;ORAL					
		MINOCYCLINE HYDROCHLORIDE					
		@ IMPAX LABS INC	EQ 45MG BASE	A 090024	001	Feb 03, 2009	Mar DISC
		@	EQ 90MG BASE	A 090024	002	Feb 03, 2009	Mar DISC
		@	EQ 135MG BASE	A 090024	003	Feb 03, 2009	Mar DISC

MINOXIDILTABLET; ORAL
MINOXIDIL

AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	----------------	------	---------	-----	--------------	----------

MIRTAZAPINETABLET; ORAL
MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
@		30MG	A076336	002	Jun 20, 2003	Jan DISC
@		45MG	A076336	003	Jun 20, 2003	Jan DISC

MITOMYCININJECTABLE; INJECTION
MITOMYCIN

>D>	AP	BEDFORD	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
>D>	AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
	AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
>A>	AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
	AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINILTABLET; ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOMETASONE FUROATESPRAY, METERED; NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
KADIAN

>D>	AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
	AB	+	10MG	N020616	008	Apr 20, 2007	Feb CTEC
>D>	AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
	AB		20MG	N020616	001	Jul 03, 1996	Feb CTEC
>D>	AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
	AB		30MG	N020616	004	Mar 09, 2001	Feb CTEC
>D>	AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
	AB		40MG	N020616	009	Jul 09, 2012	Feb CTEC
>D>	AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
	AB		50MG	N020616	002	Jul 03, 1996	Feb CTEC
>D>	AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
	AB		60MG	N020616	005	Mar 09, 2001	Feb CTEC
>D>	AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
	AB		70MG	N020616	010	Jul 09, 2012	Feb CTEC
>D>	AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
	AB		80MG	N020616	006	Oct 27, 2006	Feb CTEC
>D>	AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN
	AB	+	100MG	N020616	003	Jul 03, 1996	Feb CTEC
>D>			130MG	N020616	011	Jul 09, 2012	Apr CAHN
>D>			150MG	N020616	012	Jul 09, 2012	Apr CAHN
>D>		+	200MG	N020616	007	Feb 27, 2007	Apr CAHN
		+	200MG	N020616	007	Feb 27, 2007	Feb CTEC
>A>	AB	+	10MG	N020616	008	Apr 20, 2007	Apr CAHN
>A>	AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
>A>	AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
>A>	AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
>A>	AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
>A>	AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
>A>	AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
>A>	AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
>A>	AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN
>A>			130MG	N020616	011	Jul 09, 2012	Apr CAHN
>A>			150MG	N020616	012	Jul 09, 2012	Apr CAHN
>A>		+	200MG	N020616	007	Feb 27, 2007	Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL								
MORPHINE SULFATE								
AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar	NEWA	
AB		30MG	A200411	002	Apr 12, 2016	Mar	NEWA	
AB		50MG	A200411	003	Apr 12, 2016	Mar	NEWA	
AB		60MG	A200411	004	Apr 12, 2016	Mar	NEWA	
AB		80MG	A200411	005	Apr 12, 2016	Mar	NEWA	
AB		100MG	A200411	006	Apr 12, 2016	Mar	NEWA	
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb	CTEC	
AB		30MG	A200812	002	Nov 10, 2011	Feb	CTEC	
AB		50MG	A200812	003	Nov 10, 2011	Feb	CTEC	
AB		60MG	A200812	004	Nov 10, 2011	Feb	CTEC	
AB		80MG	A200812	005	Nov 10, 2011	Feb	CTEC	
AB		100MG	A200812	006	Nov 10, 2011	Feb	CTEC	
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb	CTEC	
AB		30MG	A202718	002	Dec 29, 2014	Feb	CTEC	
AB		40MG	A202718	007	Jun 03, 2015	Feb	CTEC	
AB		50MG	A202718	003	Dec 29, 2014	Feb	CTEC	
AB		60MG	A202718	004	Dec 29, 2014	Feb	CTEC	
AB		70MG	A202718	008	Jun 03, 2015	Feb	CTEC	
AB		80MG	A202718	005	Dec 29, 2014	Feb	CTEC	
AB		100MG	A202718	006	Dec 29, 2014	Feb	CTEC	
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb	CTEC	
AB		20MG	A202104	002	Jun 03, 2013	Feb	CTEC	
AB		30MG	A202104	003	Jun 03, 2013	Feb	CTEC	
AB		50MG	A202104	004	Jun 03, 2013	Feb	CTEC	
AB		60MG	A202104	005	Jun 03, 2013	Feb	CTEC	
AB		80MG	A202104	006	Jun 03, 2013	Feb	CTEC	
AB		100MG	A202104	007	Jun 03, 2013	Feb	CTEC	
SOLUTION;ORAL								
MORPHINE SULFATE								
AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar	CAHN	
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar	CAHN	
<u>MOXIFLOXACIN HYDROCHLORIDE</u>								
TABLET;ORAL								
MOXIFLOXACIN HYDROCHLORIDE								
AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan	NEWA	
<u>NALIDIXIC ACID</u>								
TABLET;ORAL								
NALIDIXIC ACID								
	@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar	CAHN	
	@	1GM	A070272	001	Jun 29, 1988	Mar	CAHN	
<u>NAPROXEN</u>								
TABLET;ORAL								
NAPROSYN								
AB	ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN	
AB		375MG	N017581	003		Feb	CAHN	
AB	+	500MG	N017581	004	Apr 15, 1982	Feb	CAHN	
NAPROXEN								
	@ SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb	DISC	
	@	375MG	A074140	002	Dec 21, 1993	Feb	DISC	
	@	500MG	A074140	003	Dec 21, 1993	Feb	DISC	
TABLET, DELAYED RELEASE;ORAL								
EC-NAPROSYN								
AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb	CAHN
AB	+	500MG	N020067	003	Oct 14, 1994	Feb	CAHN	
NAPROXEN								
	@ SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb	DISC	
	@	500MG	A075061	002	Feb 18, 1998	Feb	DISC	
<u>NAPROXEN SODIUM</u>								
TABLET;ORAL								
ANAPROX								
AB	ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb	CAHN	
ANAPROX DS								
AB	+	ATNAHS PHARMA US	EO 500MG BASE	N018164	003	Sep 30, 1987	Feb	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@ SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb	DISC
@	100MG	A076409	002	Sep 16, 2003	Feb	DISC
@	150MG	A076409	003	Sep 16, 2003	Feb	DISC
@	200MG	A076409	004	Sep 16, 2003	Feb	DISC
@	250MG	A076409	005	Sep 16, 2003	Feb	DISC

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

@ VALIDUS PHARMS	10MG	A073250	001	Oct 08, 1991	Mar	CAHN
@	20MG	A074045	001	Apr 30, 1992	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1	ALVOGEN	30MG	N020198	001	Apr 21, 1993	Feb	CAHN
AB1	+	60MG	N020198	002	Apr 21, 1993	Feb	CAHN
AB1	+	90MG	N020198	003	Apr 21, 1993	Feb	CAHN
	NIFEDIPINE						
AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan	CAHN
AB1		60MG	A075269	002	Dec 04, 2000	Jan	CAHN
AB1		90MG	A076070	001	Aug 16, 2002	Jan	CAHN

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
----	---	----------------	------	---------	-----	--------------	-----	------

NITISINONE

>A> SUSPENSION; ORAL

>A> ORFADIN

>A>	+	SOBI	4MG/ML	N206356	001	Apr 22, 2016	Apr	NEWA
-----	---	------	--------	---------	-----	--------------	-----	------

NITRIC OXIDE

GAS; INHALATION

INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan	CAHN
---	-------------------	--------	---------	-----	--------------	-----	------

NITROFURANTOIN

SUSPENSION; ORAL

NITROFURANTOIN

>A>	AB	ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA
	AB	NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

AB	SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA
AB		50MG	A201722	002	Feb 16, 2016	Feb	NEWA
AB		100MG	A201722	003	Feb 16, 2016	Feb	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALVOGEN MALTA	75MG; 25MG	N020064	001	Dec 24, 1991	Jan	CAHN
----	---	---------------	------------	---------	-----	--------------	-----	------

NIZATIDINE

SOLUTION; ORAL

AXID

@ BRAINTREE	15MG/ML	N021494	001	May 25, 2004	Feb	DISC
-------------	---------	---------	-----	--------------	-----	------

NIZATIDINE

+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb	CRLD
---	---------------	---------	---------	-----	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

>D>	AP	BEDFORD	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr	CAHN
	AP	CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr	CAHN

NORETHINDRONE

TABLET; ORAL-28

NOR-QD

AB1	+	APIL	0.35MG	N017060	001		Jan	CAHN
-----	---	------	--------	---------	-----	--	-----	------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE

A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE

A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE

A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE

A074835 004 Jun 30, 1997 Feb CAHN

NYSTATIN

TABLET; ORAL

NYSTATIN

AA		SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM 100,000 UNITS/GM; 0.1%

A062596 001 Oct 08, 1985 Mar CMS1

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

@ WOCKHARDT USA EQ 0.2MG BASE/ML

A090986 001 May 11, 2011 Jan DISC

@ EQ 1MG BASE/ML

A090986 002 May 11, 2011 Jan DISC

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

@ WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Jan DISC

@ EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Jan DISC

@ EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Jan DISC

OCTREOTIDE ACETATE PRESERVATIVE FREE

@ WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Feb CMS1

@ EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Feb CMS1

@ EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Feb CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT		ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar	CAHN
----	--	---------	------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OTIC

FLOXIN OTIC

@ DAIICHI 0.3%

N020799 001 Dec 16, 1997 Feb DISC

OFLOXACIN

AT		ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar	CAHN
----	--	---------	------	---------	-----	--------------	-----	------

AT	+	BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb	CRLD
----	---	-----------------	------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AB		INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

AB			5MG	A203333	002	Mar 15, 2016	Feb	NEWA
----	--	--	-----	---------	-----	--------------	-----	------

AB			7.5MG	A203333	003	Mar 15, 2016	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			10MG	A203333	004	Mar 15, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			15MG	A203333	005	Mar 15, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			20MG	A203333	006	Mar 15, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB		QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

AB			5MG	A204319	002	Jan 27, 2016	Jan	NEWA
----	--	--	-----	---------	-----	--------------	-----	------

AB			7.5MG	A204319	003	Jan 27, 2016	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			10MG	A204319	004	Jan 27, 2016	Jan	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			15MG	A204319	005	Jan 27, 2016	Jan	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			20MG	A204319	006	Jan 27, 2016	Jan	NEWA
----	--	--	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB		INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb	NEWA
----	--	----------------	-----	---------	-----	--------------	-----	------

AB			10MG	A203456	002	Mar 16, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			15MG	A203456	003	Mar 16, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			20MG	A203456	004	Mar 16, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	---------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE;ORAL
OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Mar CAIN
---	-------	--	---------	-----	--------------	----------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

>D>	AP	BEDFORD	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
>D>	AP	BEDFORD LABS	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN

OXALIPLATININJECTABLE;IV (INFUSION)
OXALIPLATIN

>A>	AP	QILU PHARM CO LTD	50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
>A>	AP		100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
	AP	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan CAHN
	AP		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan CAHN

OXAZEPAMCAPSULE;ORAL
OXAZEPAM

@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar CAHN

OXICONAZOLE NITRATECREAM;TOPICAL
OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA	
	OXISTAT						
AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

>D>	AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
>A>	AB	+	ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN

GEL, METERED;TRANSDERMAL
GELNIQUE 3%

>D>		+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Apr CAHN
>A>		+	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDEGEL;TRANSDERMAL
GELNIQUE

>D>	+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN
>A>	+	ALLERGAN SALES LLC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB		10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB		15MG	A207138	003	Feb 29, 2016	Feb NEWA

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar NEWA
----	----------------	-----	---------	-----	--------------	----------

>A> CAPSULE, EXTENDED RELEASE;ORAL

>A> XTAMPZA ER

>A>	COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr NEWA
>A>		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr NEWA
>A>		EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr NEWA
>A>		EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr NEWA
>A>		EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN
AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN
>A> AB	COASTAL PHARMS	10MG	A091313	004	Apr 29, 2016	Apr NEWA
>A> AB		20MG	A091313	005	Apr 29, 2016	Apr NEWA
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

>A> AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr NEWA
>A> AB		10MG	A204459	002	Apr 26, 2016	Apr NEWA

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN
----	------------	--------	---------	-----	--------------	----------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar CRLD
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>A> AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr NEWA
>A> AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr NEWA

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar NEWA
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar NEWA

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar NEWA
	TABLET, DELAYED RELEASE;ORAL					
	PANTOPRAZOLE SODIUM					
AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN
AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb NEWA
AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA

SOLUTION;INTRAVENOUS
PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA

PENBUTOLOL SULFATE

TABLET;ORAL
LEVATOL

@	AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Mar CAHN
@		20MG	N018976	004	Jan 05, 1989	Mar CAHN

>A> PENCICLOVIR

>A> CREAM;TOPICAL
>A> DENAVIR

>A>	+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr CAIN
-----	---	-------------	----	---------	-----	--------------	----------

>D> PENCICLOVIR SODIUM

>D> CREAM;TOPICAL
>D> DENAVIR

>D>	+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr CAIN
-----	---	-------------	----	---------	-----	--------------	----------

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

>D>	@	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr CMFD
>A>	+		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr CMFD
	@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb CAHN

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

>D>	@	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr CMFD
>A>	+		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr CMFD
	@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar DISC
	TRENTAL						
	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CAHN

PERAMPANEL

>A> SUSPENSION;ORAL
 >A> FYCOMPA
 >A> + EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016 Apr NEWA

PERPHENAZINE

TABLET;ORAL
 PERPHENAZINE
 AB WILSHIRE PHARMS INC 2MG A205973 001 Dec 17, 2015 Jan CAHN
 AB 4MG A205973 002 Dec 17, 2015 Jan CAHN
 AB 8MG A205973 003 Dec 17, 2015 Jan CAHN
 AB 16MG A205973 004 Dec 17, 2015 Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL
 SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE
 @ ABLE 200MG,N/A,N/A;N/A,800MG,160MG N021105 001 Jun 26, 2001 Jan CMS1

PHTERMINE HYDROCHLORIDE

CAPSULE;ORAL
 PHTERMINE HYDROCHLORIDE
 AA SUN PHARM INDS 30MG A040525 001 Oct 23, 2003 Mar CAHN
 @ 37.5MG A040527 001 Oct 23, 2003 Mar CAHN
 TABLET;ORAL
 PHTERMINE HYDROCHLORIDE
 AA INGENUS PHARMS NJ 37.5MG A091451 001 Sep 21, 2012 Jan CAHN
 AA SUN PHARM INDS 37.5MG A040526 001 Oct 23, 2003 Mar CAHN

PHENYLBUTAZONE

CAPSULE;ORAL
 PHENYLBUTAZONE
 @ SUN PHARM INDS 100MG A088994 001 Dec 04, 1985 Mar CAHN
 TABLET;ORAL
 PHENYLBUTAZONE
 @ SUN PHARM INDS 100MG A088863 001 Dec 04, 1985 Mar CAHN

PHYTONADIONE

INJECTABLE;INJECTION
 AQUAMEPHYTON
 @ TELIGENT PHARMA INC 1MG/0.5ML N012223 002 Jan CAHN
 @ 10MG/ML N012223 001 Jan CAHN

>A> PIMAVANSERIN TARTRATE

>A> TABLET;ORAL
 >A> NUPLAZID
 >A> + ACADIA PHARMS INC EQ 17MG BASE N207318 001 Apr 29, 2016 Apr NEWA

PINDOLOL

TABLET;ORAL
 PINDOLOL
 AB SUN PHARM INDS 5MG A074063 001 Jan 27, 1994 Mar CAHN
 AB 10MG A074063 002 Jan 27, 1994 Mar CAHN

PIROXICAM

CAPSULE;ORAL
 PIROXICAM
 AB MYLAN PHARMS INC 20MG A074118 001 Jun 15, 1993 Jan CAHN
 @ SUN PHARM INDS 20MG A073536 001 Mar 12, 1993 Mar CAHN

PODOFILOX

GEL;TOPICAL
 CONDYLOX
 + ALLERGAN SALES LLC 0.5% N020529 001 Mar 13, 1997 Mar CAHN
 SOLUTION;TOPICAL
 CONDYLOX
 AT + ALLERGAN SALES LLC 0.5% N019795 001 Dec 13, 1990 Mar CAHN

POLYMYXIN B SULFATE

INJECTABLE;INJECTION
POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar NEWA
>A> AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan NEWA
AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar NEWA
AB		10MEQ	A204210	002	Mar 28, 2016	Mar NEWA
AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb NEWA
AB		10MEQ	A201944	002	Mar 04, 2016	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1	NOVEL LABS INC	10MEQ	A206347	001	Jan 21, 2016	Jan NEWA
AB1		20MEQ	A206347	002	Jan 21, 2016	Jan NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>A> AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
>A> AB		0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
>A> AB		1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
>A> AB		3MG	A201963	004	Apr 21, 2016	Apr NEWA
>A> AB		4.5MG	A201963	005	Apr 21, 2016	Apr NEWA

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE

@ AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
-----------------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL
ORAPRED

@ CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar DISC
PREDNISOLONE SODIUM PHOSPHATE					
AA + WOCHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD

PREDNISONE

TABLET;ORAL
PREDNISONE

@ AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
@	10MG	A089983	001	Jan 12, 1989	Mar CAHN
@	20MG	A085813	001		Mar CAHN
@	50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN
AB	10MG	A088832	001	Dec 04, 1985	Mar CAHN
AB	20MG	A083677	001		Mar CAHN
AB SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN

PRIMIDONE

TABLET;ORAL
PRIMIDONE

@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar DISC
@	250MG	A040717	002	Feb 12, 2008	Mar DISC
AB SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar CAHN
AB	250MG	A040626	002	Sep 29, 2005	Mar CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

>D>	AP	BEDFORD	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr CAHN

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL;VAGINAL
CRINONE

>D>	+	ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Apr CAHN
>D>	+		8%	N020701	002	Jul 31, 1997	Apr CAHN
>A>	+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr CAHN
>A>	+		8%	N020701	002	Jul 31, 1997	Apr CAHN

INJECTABLE;INJECTION
PROGESTERONE

>D>	AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002	Apr CAHN
>A>	AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002	Apr CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb CAHN
----	------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

@	IMPAX LABS	12.5MG
@		25MG
@		50MG
@	SUN PHARM INDS	12.5MG
@		25MG
@		50MG

A040724	001	Feb 12, 2008	Mar DISC
A040724	002	Feb 12, 2008	Mar DISC
A040791	001	May 20, 2008	Mar DISC
A084555	001		Mar CAHN
A084554	001		Mar CAHN
A084557	001		Jan CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr NEWA
>A>	AB		325MG	A203803	002	Apr 29, 2016	Apr NEWA
>A>	AB		425MG	A203803	003	Apr 29, 2016	Apr NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

>A>	AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr NEWA
>A>	AB		225MG	A202445	002	May 11, 2016	Apr NEWA
>A>	AB		300MG	A202445	003	May 11, 2016	Apr NEWA
	AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar CAHN
	AB		225MG	A075998	002	Nov 29, 2001	Mar CAHN
	AB		300MG	A075998	003	Nov 29, 2001	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
INDERAL LA

>A>	AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr CAHN
>A>	AB		80MG	N018553	002	Apr 19, 1983	Apr CAHN
>A>	AB		120MG	N018553	003	Apr 19, 1983	Apr CAHN
>A>	AB	+	160MG	N018553	001	Apr 19, 1983	Apr CAHN
>D>	AB	CRANFORD PHARMS LLC	60MG	N018553	004	Mar 18, 1987	Apr CAHN
>D>	AB		80MG	N018553	002	Apr 19, 1983	Apr CAHN
>D>	AB		120MG	N018553	003	Apr 19, 1983	Apr CAHN
>D>	AB	+	160MG	N018553	001	Apr 19, 1983	Apr CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG
BX		80MG
BX		120MG
BX		160MG

A078311	001	Mar 06, 2009	Mar CTEC
A078311	002	Mar 06, 2009	Mar CTEC
A078311	003	Mar 06, 2009	Mar CTEC
A078311	004	Mar 06, 2009	Mar CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

>D>	AP	BEDFORD	1MG/ML	A075792	001	Aug 29, 2000	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr CAHN
		@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar CAHN
@	20MG	A070320	001	Oct 22, 1985	Mar CAHN
@	40MG	A070103	001	Oct 22, 1985	Mar CAHN
@	80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

@ SUN PHARM INDS	50MG	A083982	001		Mar CAHN
------------------	------	---------	-----	--	----------

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

QUAZEPAM

TABLET;ORAL

DORAL

>D>	@ CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar CAHN
>A>	+	15MG	N018708	001	Dec 27, 1985	Apr CMFD
	@	15MG	N018708	001	Dec 27, 1985	Apr CMFD
	@	15MG	N018708	001	Dec 27, 1985	Mar CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

>D>	AB	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr DISC
>A>		@	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr DISC
>D>	AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr DISC
>A>		@	EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr DISC
>D>	AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr DISC
>A>		@	EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr DISC
>D>	AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr DISC
>A>		@	EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr DISC
>D>	AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr DISC
>A>		@	EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr DISC
>D>	AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr DISC
>A>		@	EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr DISC
>D>	AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr DISC
>A>		@	EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr DISC
	AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
	AB		EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
	AB		EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
	AB		EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
	AB		EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
	AB		EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan DISC
@	EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan DISC
@	EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan DISC
@	EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

BX	+	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar CAHN
		SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

AB	SUN PHARM INDS	200MG	A081030	001	Apr 14, 1989	Mar CAHN
AB		300MG	A081031	001	Apr 14, 1989	Mar CAHN

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB	AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar NEWA
AB	GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
	ZANTAC IN PLASTIC CONTAINER					
	@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
>D> AA	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
>A>	@	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
>D> AA		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC
>A>	@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET; ORAL

RESERPINE

@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
@		0.25MG	A080975	002		Feb CAHN
@		1MG	A080975	003		Feb CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN
---	-----------------	----	---------	-----	--------------	----------

>A> RIBOFLAVIN 5'-PHOSPHATE SODIUM

>A> SOLUTION/DROPS; OPHTHALMIC

>A> PHOTREXA

>A>	+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr NEWA
-----	---	------------	--------	---------	-----	--------------	----------

>A> PHOTREXA VISCOUS IN DEXTROSE 20%

>A>	+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr NEWA
-----	---	------------	--------	---------	-----	--------------	----------

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

>D> AP	BEDFORD	600MG/VIAL	A064217	001	Oct 29, 1999	Apr CAHN
>A> AP	EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr CAHN
AP	HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
AP	WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA

RILUZOLE

TABLET; ORAL

RILUZOLE

AB	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar NEWA
----	----------------	------	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
----	---	------	------	---------	-----	--------------	----------

RISPERIDONESOLUTION; ORAL
RISPERIDONE

>D>	AA	WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC
>A>		@	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC

RIVASTIGMINEFILM, EXTENDED RELEASE; TRANSDERMAL
RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATECAPSULE; ORAL
EXELON

AB	+ NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
	RIVASTIGMINE TARTRATE					
AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB		EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB		EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB		EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATETABLET; ORAL
RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
----	-----------	--------	---------	-----	--------------	----------

SOLUTION; INJECTION
NAROPIN

AP	FRESENIUS KABI USA	20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
>A>	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
>A>		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA
>D>		500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Apr CMS1
>A>		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
		500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
>D>		1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Apr CMS1
>A>		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
		1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA

ROPIVACAINE HYDROCHLORIDE

AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar CDFR

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

>D>	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG	
>A>	AB	5MG	N021366	002	Aug 12, 2003	Apr	CFTG	
>D>		10MG	N021366	003	Aug 12, 2003	Apr	CFTG	
>A>	AB	10MG	N021366	003	Aug 12, 2003	Apr	CFTG	
>D>		20MG	N021366	004	Aug 12, 2003	Apr	CFTG	
>A>	AB	20MG	N021366	004	Aug 12, 2003	Apr	CFTG	
>D>	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG	
>A>	AB	40MG	N021366	005	Aug 12, 2003	Apr	CFTG	
>A>	ROSUVASTATIN CALCIUM							
>A>	AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
>A>	AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
>A>	AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
>A>	AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE

A077818 001 Feb 06, 2007 Mar CAHN
 A077818 002 Feb 06, 2007 Mar CAHN
 A077818 003 Feb 06, 2007 Mar CAHN

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

>D>	AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
>A>		@	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
		@ TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA
		@	EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA
		@	EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

>D>	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
>D>			8MG	N022206	002	Oct 08, 2008	Apr	CAHN
>A>	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
>A>			8MG	N022206	002	Oct 08, 2008	Apr	CAHN

SIMVASTATIN

>A>	SUSPENSION;ORAL							
>A>	SIMVASTATIN							
>A>	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr	NEWA	
>A>	+	40MG/5ML	N206679	002	Apr 21, 2016	Apr	NEWA	
	TABLET;ORAL							
	SIMVASTATIN							
	@ SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb	DISC	
	@	10MG	A076285	002	Dec 20, 2006	Feb	DISC	
	@	20MG	A076285	003	Dec 20, 2006	Feb	DISC	
	@	40MG	A076285	004	Dec 20, 2006	Feb	DISC	
	@	80MG	A076285	005	Jun 23, 2006	Feb	DISC	

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG
		SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

HOSPIRA INC 0.5MEQ/ML

A202981 001 Mar 04, 2016 Feb NEWA

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS						
SODIUM FLUORIDE F-18						
AP	ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL						
SODIUM IODIDE I 131						
	JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Mar CMS1
	@	2-200mCi	N021305	004	Nov 18, 2004	Mar CMS1

SODIUM PHENYL BUTYRATE

POWDER;ORAL						
BUPHENYL						
AB	+ HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CAHN
TABLET;ORAL						
BUPHENYL						
AB	+ HORIZON PHARMA USA	500MG	N020572	001	May 13, 1996	Mar CAHN
SODIUM PHENYL BUTYRATE						
>A> AB	PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL						
SODIUM POLYSTYRENE SULFONATE						
AA	BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
AA	INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL						
SOTALOL HYDROCHLORIDE						
	@ IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar DISC
	@	120MG	A075663	002	Nov 07, 2000	Mar DISC
	@	160MG	A075663	003	Nov 07, 2000	Mar DISC
	@	240MG	A075663	004	Nov 07, 2000	Mar DISC
	@ SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar CAHN
	@	80MG	A076576	001	Apr 08, 2004	Mar CAHN
	@	120MG	A075515	004	Oct 15, 2001	Mar CAHN
	@	120MG	A076576	002	Apr 08, 2004	Mar CAHN
	@	160MG	A075515	002	Oct 15, 2001	Mar CAHN
	@	160MG	A076576	003	Apr 08, 2004	Mar CAHN
	@	240MG	A075515	003	Oct 15, 2001	Mar CAHN

SPIRONOLACTONE

TABLET;ORAL						
SPIRONOLACTONE						
AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar CAHN

SUCRALFATE

TABLET;ORAL						
SUCRALFATE						
AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS						
BRIDION						
	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULFAMETHOXAZOLE

TABLET;ORAL						
SULFAMETHOXAZOLE						
	@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL							
BACTRIM							
AB	SUN PHARM INDS	400MG;80MG	N017377	001			Mar CAHN
BACTRIM DS							
AB	+ SUN PHARM INDS	800MG;160MG	N017377	002			Mar CAHN
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AB	SUN PHARM INDS	800MG;160MG	A071017	001	Aug 25, 1986		Mar CAHN

SULFASALAZINE

TABLET; ORAL							
SULFASALAZINE							
	@ SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987		Mar CAHN

SULFISOXAZOLE

TABLET; ORAL							
SULFISOXAZOLE							
	@ AUROLIFE PHARMA LLC	500MG	A085628	001			Feb CAHN

SULINDAC

TABLET; ORAL							
SULINDAC							
AB	SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991		Mar CAHN
AB		200MG	A072051	001	Apr 17, 1991		Mar CAHN

SUMATRIPTAN

SPRAY; NASAL							
IMITREX							
AB	+ GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997		Feb CFTG
AB	+	20MG/SPRAY	N020626	003	Aug 26, 1997		Feb CFTG
SUMATRIPTAN							
AB	LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016		Feb NEWA
AB		20MG/SPRAY	A204841	002	Feb 19, 2016		Feb NEWA

SUMATRIPTAN SUCCINATE

POWDER; INHALATION							
ONZETRA XSAIL							
	+ AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016		Jan NEWA
SOLUTION; SUBCUTANEOUS							
ZEMBRACE SYMTOUCH							
	DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016		Jan NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL							
SOLTAMOX							
	MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005		Jan CAHN
TABLET; ORAL							
TAMOXIFEN CITRATE							
	@ ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003		Jan DISC
	@	EQ 20MG BASE	A076179	002	Feb 20, 2003		Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS							
ULTRA-TECHNEKOW FM							
	+ MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014		Jan CAHN
	@	0.25-3 CI/GENERATOR	N017243	002			Jan CAHN

TEGASEROD MALEATE

TABLET; ORAL							
ZELNORM							
	@ US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002		Jan CAHN
	@	EQ 6MG BASE	N021200	002	Jul 24, 2002		Jan CAHN

TELITHROMYCIN

TABLET; ORAL							
KETEK							
	@ SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005		Mar DISC
	@	400MG	N021144	001	Apr 01, 2004		Mar DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

>A>	AB	HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Apr	NEWA
>A>	AB		40MG	A205901	002	Apr 22, 2016	Apr	NEWA
>A>	AB		80MG	A205901	003	Apr 22, 2016	Apr	NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB		SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
		@	15MG	A071174	001	Jul 10, 1986	Mar	CAHN
AB			22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
		@	30MG	A071175	001	Jul 10, 1986	Mar	CAHN

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB		IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
AB			20MG	A206413	002	Apr 12, 2016	Mar	NEWA
AB			100MG	A206413	003	Apr 12, 2016	Mar	NEWA
AB			140MG	A206413	004	Apr 12, 2016	Mar	NEWA
AB			180MG	A206413	005	Apr 12, 2016	Mar	NEWA
AB			250MG	A206413	006	Apr 12, 2016	Mar	NEWA
AB		KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
AB			20MG	A203898	002	Feb 10, 2016	Jan	NEWA
AB			100MG	A203898	003	Feb 10, 2016	Jan	NEWA
AB			140MG	A203898	004	Feb 10, 2016	Jan	NEWA
AB			180MG	A203898	005	Feb 10, 2016	Jan	NEWA
AB			250MG	A203898	006	Feb 10, 2016	Jan	NEWA
AB		LANNETT HOLDINGS INC	5MG	A202750	001	Mar 23, 2016	Mar	NEWA
AB			20MG	A202750	002	Mar 23, 2016	Mar	NEWA
AB			100MG	A202750	003	Mar 23, 2016	Mar	NEWA
AB			140MG	A202750	004	Mar 23, 2016	Mar	NEWA
AB			180MG	A202750	005	Mar 23, 2016	Mar	NEWA
AB			250MG	A202750	006	Mar 23, 2016	Mar	NEWA
>A>	AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Apr	NEWA
>A>	AB		20MG	A206309	002	Apr 27, 2016	Apr	NEWA
>A>	AB		100MG	A206309	003	Apr 27, 2016	Apr	NEWA
>A>	AB		140MG	A206309	004	Apr 27, 2016	Apr	NEWA
>A>	AB		180MG	A206309	005	Apr 27, 2016	Apr	NEWA
>A>	AB		250MG	A206309	006	Apr 27, 2016	Apr	NEWA

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

>D>	AP	+	BEDFORD	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN
>A>	AP	+	EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN

TABLET; ORAL

TERBUTALINE SULFATE

@ IMPAX LABS

@

LANNETT

2.5MG

5MG

2.5MG

5MG

A075877	001	Jun 26, 2001	Mar	DISC
A075877	002	Jun 26, 2001	Mar	DISC
A077152	001	Mar 25, 2005	Mar	CTEC
A077152	002	Mar 25, 2005	Mar	CTEC

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+	ALLERGAN SALES LLC	2MG/24HR
@		2.5MG/24HR
+		4MG/24HR
@		5MG/24HR

N020489	003	Oct 20, 2011	Mar	CAHN
N020489	001	Sep 29, 1995	Mar	CAHN
N020489	004	Oct 20, 2011	Mar	CAHN
N020489	002	May 02, 1997	Mar	CAHN

PELLET; IMPLANTATION

TESTOPEL

+	AUXILIUM PHARMS INC	75MG
---	---------------------	------

A080911	001		Mar	CAHN
---------	-----	--	-----	------

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+	AUXILIUM PHARMS INC	30MG
---	---------------------	------

N021543	001	Jun 19, 2003	Mar	CAHN
---------	-----	--------------	-----	------

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb NEWA
---	---------------	------	---------	-----	--------------	----------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

>D>	@ CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr CMFD
>A> AB		250MG	A062752	001	Aug 12, 1988	Apr CMFD
>D>	@	500MG	A062752	002	Aug 12, 1988	Apr CMFD
>A> AB		500MG	A062752	002	Aug 12, 1988	Apr CMFD
	@ SUN PHARM INDS	250MG	A060736	001		Mar CAHN
	@	500MG	A060736	002		Mar CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

AUXILIUM PHARMS INC

200MG

A087943	001	Aug 22, 1983	Mar CAHN
---------	-----	--------------	----------

300MG

A087944	001	Aug 22, 1983	Mar CAHN
---------	-----	--------------	----------

+

400MG

A081034	001	Feb 28, 1992	Mar CAHN
---------	-----	--------------	----------

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

+

NOSTRUM LABS INC

80MG/15ML

A085186	001		Jan CAHN
---------	-----	--	----------

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB NOSTRUM LABS INC

100MG

A088320	001	Feb 21, 1985	Jan CAHN
---------	-----	--------------	----------

AB

200MG

A088321	001	Feb 21, 1985	Jan CAHN
---------	-----	--------------	----------

@

300MG

A087400	002	Jan 11, 1983	Jan CAHN
---------	-----	--------------	----------

THEOPHYLLINE

AB MYLAN IRELAND LTD

400MG

A040560	003	Apr 21, 2006	Jan CAHN
---------	-----	--------------	----------

AB

+

600MG

A040560	002	Apr 21, 2006	Jan CAHN
---------	-----	--------------	----------

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB SUN PHARM INDS

10MG

A089953	004	Aug 01, 1986	Mar CAHN
---------	-----	--------------	----------

@

15MG

A088461	001	Nov 18, 1983	Mar CAHN
---------	-----	--------------	----------

AB

25MG

A089953	003	Aug 01, 1986	Mar CAHN
---------	-----	--------------	----------

AB

50MG

A089953	002	Aug 01, 1986	Mar CAHN
---------	-----	--------------	----------

AB

100MG

A089953	001	Oct 07, 1988	Mar CAHN
---------	-----	--------------	----------

@

150MG

A088737	001	Sep 26, 1984	Mar CAHN
---------	-----	--------------	----------

@

200MG

A088738	001	Oct 16, 1984	Mar CAHN
---------	-----	--------------	----------

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

@ SANDOZ

1MG

A071610	001	Jun 24, 1987	Mar DISC
---------	-----	--------------	----------

@

2MG

A071570	001	Jun 24, 1987	Mar DISC
---------	-----	--------------	----------

@

5MG

A071529	001	Jun 24, 1987	Mar DISC
---------	-----	--------------	----------

@

10MG

A071530	001	Jun 24, 1987	Mar DISC
---------	-----	--------------	----------

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

>D> AB UNIQUE PHARM LABS

250MG

A202489	001	Oct 09, 2013	Apr CTEC
---------	-----	--------------	----------

>A> BX

250MG

A202489	001	Oct 09, 2013	Apr CTEC
---------	-----	--------------	----------

>D> AB

500MG

A202489	002	Oct 09, 2013	Apr CTEC
---------	-----	--------------	----------

>A> BX

500MG

A202489	002	Oct 09, 2013	Apr CTEC
---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

+ PFIZER INC EQ 11MG BASE N208246 001 Feb 23, 2016 Feb NEWA

TOLAZAMIDE

TABLET;ORAL
TOLAZAMIDE

@ SUN PHARM INDS 100MG A071357 001 Jul 16, 1987 Mar CAHN
@ 250MG A071358 001 Jul 16, 1987 Mar CAHN
@ 500MG A071359 001 Jul 16, 1987 Mar CAHN

TOLMETIN SODIUM

CAPSULE;ORAL
TOLMETIN SODIUM

@ SUN PHARM INDS EQ 400MG BASE A073311 001 Nov 27, 1991 Mar CAHN

TABLET;ORAL

TOLMETIN SODIUM
AB SUN PHARM INDS EQ 200MG BASE A073310 001 Nov 27, 1991 Mar CAHN

TOPIRAMATE

TABLET;ORAL
TOPIRAMATE

>D> AB ACTAVIS TOTOWA 25MG A078637 001 Feb 27, 2013 Apr DISC
>A> @ 25MG A078637 001 Feb 27, 2013 Apr DISC
AB 25MG A078637 001 Feb 27, 2013 Jan CAHN
>D> AB 50MG A078637 002 Feb 27, 2013 Apr DISC
>A> @ 50MG A078637 002 Feb 27, 2013 Apr DISC
AB 50MG A078637 002 Feb 27, 2013 Jan CAHN
>D> AB 100MG A078637 003 Feb 27, 2013 Apr DISC
>A> @ 100MG A078637 003 Feb 27, 2013 Apr DISC
AB 100MG A078637 003 Feb 27, 2013 Jan CAHN
>D> AB 200MG A078637 004 Feb 27, 2013 Apr DISC
>A> @ 200MG A078637 004 Feb 27, 2013 Apr DISC
AB 200MG A078637 004 Feb 27, 2013 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB ACI HEALTHCARE LTD 50MG A202075 001 Nov 28, 2011 Mar CAHN
AB SUN PHARM INDS 50MG A076100 001 Jun 20, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
ULTRAM ER

AB1 + VALEANT PHARMS 100MG N021692 001 Sep 08, 2005 Mar CAHN
AB1 200MG N021692 002 Sep 08, 2005 Mar CAHN
AB1 300MG N021692 003 Sep 08, 2005 Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

AP AUROBINDO PHARMA LTD 100MG/ML A205035 001 Jan 14, 2016 Jan NEWA
AP NORTH CREEK PHARMS 100MG/ML A202755 001 Feb 25, 2016 Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL
TRAZODONE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 50MG A072484 001 Apr 30, 1990 Feb CAHN
AB SUN PHARM INDS 50MG A073137 002 Mar 24, 1993 Mar CAHN
AB 100MG A073137 001 Mar 24, 1993 Mar CAHN
AB 150MG A073137 003 Dec 22, 1995 Mar CAHN

TRETINOIN

CREAM;TOPICAL
TRETINOIN

AB ELAN PHARMA INTL LTD 0.025% A075264 001 Dec 24, 1998 Feb CAHN
AB1 0.05% A075265 001 Dec 24, 1998 Feb CAHN
AB 0.1% A075213 001 Dec 24, 1998 Feb CAHN

GEL;TOPICAL
TRETINOIN

AB ELAN PHARMA INTL LTD 0.01% A075589 001 Jun 11, 2002 Feb CAHN
AB 0.025% A075529 001 Feb 22, 2000 Feb CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

	@ SUN PHARM INDS	200MG	A070495	001	Sep 24, 1986	Mar CAHN
--	------------------	-------	---------	-----	--------------	----------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

@ AYTU PHARMS

EQ 25MG BASE/5ML

A074374	001	Jun 23, 1995	Jan CAHN
---------	-----	--------------	----------

+

EQ 50MG BASE/5ML

N074973	001	Jan 24, 2000	Jan CAHN
---------	-----	--------------	----------

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

>A> AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
>A> AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
>A> AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

>D>	+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
>D>	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
>D>	+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN
>A>	+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
>A>	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
>A>	+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIMUM CHLORIDE

>D> AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr DISC
>A>	@	60MG	A091635	001	Apr 29, 2015	Apr DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

@ R-TECH UENO LTD

0.15%

N021214	001	Aug 03, 2000	Mar DISC
---------	-----	--------------	----------

@ SUCAMPO PHARMA LLC

0.15%

N021214	001	Aug 03, 2000	Mar CAHN
---------	-----	--------------	----------

URSODIOL

CAPSULE;ORAL

ACTIGALL

@ ALLERGAN SALES LLC

150MG

N019594	001	Dec 31, 1987	Mar CAHN
---------	-----	--------------	----------

AB	+	300MG	N019594	002	Dec 31, 1987	Mar CAHN
----	---	-------	---------	-----	--------------	----------

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

>D> AP	BEDFORD	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN
>A> AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

SYRUP;ORAL

VALPROIC ACID

AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	------------------	-----------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar	NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar	NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

>D>	AP	BEDFORD	10MG/VIAL	A075549	001	Jun 13, 2000	Apr	CAHN
>D>	AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr	CAHN
>A>	AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr	CAHN
>A>	AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr	CAHN
	AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan	CAHN
	AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan	CAHN

>A> VENETOCLAX

>A> TABLET; ORAL
>A> VENCLEXTA

>A>		ABBVIE INC	10MG	N208573	001	Apr 11, 2016	Apr	NEWA
>A>			50MG	N208573	002	Apr 11, 2016	Apr	NEWA
>A>		+	100MG	N208573	003	Apr 11, 2016	Apr	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
CALAN

>D>		@ EXELA PHARMA SCS LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Apr	CMFD
		SOLUTION; INTRAVENOUS						
		VERAPAMIL HYDROCHLORIDE						
>A>	AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr	CMFD
		TABLET, EXTENDED RELEASE; ORAL						
		CALAN SR						
		@ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb	DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

>D>	AP	BEDFORD	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr	CAHN

VORICONAZOLE

FOR SUSPENSION; ORAL
VORICONAZOLE

AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA
	INJECTABLE; IV (INFUSION)						
	VORICONAZOLE						
AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar	NEWA
	TABLET; ORAL						
	VORICONAZOLE						
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan	NEWA

XENON XE-133

GAS; INHALATION
XENON XE 133

	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD

ZOLMITRIPTAN

TABLET; ORAL
ZOLMITRIPTAN

>A>	AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr	NEWA
>A>	AB		5MG	A207021	002	May 11, 2016	Apr	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar CAHN
@	10MG	A077288	002	Apr 23, 2007	Mar CAHN

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN
	ZONISAMIDE					
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG; 250MG; 65MG

N020802 001 Jan 14, 1998 Feb CAHN

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

>A> APOTEX INC 0.032MG/SPRAY

A078949 002 Nov 20, 2015 Apr NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 004 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009 Jan CAHN

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008 Apr DISC

>A> @ 5MG/5ML

A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008 Apr DISC

>A> @ 5MG/5ML

A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG

A206793 001 Mar 08, 2016 Feb NEWA

10MG

A206793 002 Mar 08, 2016 Feb NEWA

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 12MG

A070797 001 Aug 12, 1988 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A> AUROBINDO PHARMA LTD 10MG

A206531 001 Apr 26, 2016 Apr NEWA

>A> 20MG

A206531 002 Apr 26, 2016 Apr NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

APOTEX TECHNOLOGIES 0.05MG/SPRAY

A208150 001 Feb 29, 2016 Feb NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BIONPHARMA INC 200MG

N021472 001 Oct 18, 2002 Jan CAHN

TABLET; ORAL

IBUPROFEN

@ SUN PHARM INDS 200MG

A070493 001 Dec 24, 1985 Mar CAHN

@ 200MG

A070908 001 Sep 26, 1986 Mar CAHN

@ 200MG

A071462 001 Oct 02, 1986 Mar CAHN

LEVONORGESTREL

TABLET;ORAL

HER STYLE

NOVAST LABS LTD

1.5MG

A207976 001 Mar 11, 2016 Feb NEWA

LEVONORGESTREL

GLENMARK PHARMS LTD

1.5MG

A207044 001 Mar 25, 2016 Mar NEWA

>A> + PERRIGO R AND D 0.75MG

A090740 001 Dec 30, 2010 Apr CRLD

>A> @ WATSON LABS 0.75MG

A078665 001 Aug 28, 2009 Apr DISC

PLAN B

>A> @ TEVA BRANDED PHARM 0.75MG

N021045 002 Aug 24, 2006 Apr DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+

2MG

N021855 002 Aug 04, 2005 Jan CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,200MG

N020670 002 Apr 16, 1996 Mar CMS1

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC

EQ 200MG BASE

N021920 001 Feb 17, 2006 Mar CAHN

TABLET;ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD

EQ 200MG BASE

A205497 001 Mar 18, 2016 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

>A> ACTAVIS LABS NY INC EQ 2MG BASE

A204794 001 May 10, 2016 Apr NEWA

EQ 4MG BASE

A204833 001 Feb 26, 2016 Feb NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO

65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2016

NO APRIL 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 003					>A> I-730	Apr 15, 2019
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		>A> NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					>A> M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					>A> M-177	Apr 05, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	>A> 9216150	Sep 29, 2032	DP			
	>A> 9226892	Sep 29, 2032			U-1731	
	>A> 9226892	Sep 29, 2032			U-1732	
	>A> 9226892	Sep 29, 2032			U-1733	
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP		U-155	
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP		U-155	
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP		U-155	
<u>AXITINIB - INLYTA</u>						
N 202324 001	>A> 6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	>A> 6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023			U-644	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001					NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001 >A>	9295641	Jul 10, 2021	U-1833			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001 >A>	9295641	Jul 10, 2021	U-1833			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	Feb 18, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001 >A>	8778999	Sep 03, 2029	DP U-1834		>A> NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					>A> M-178	Apr 29, 2019
					>A> NPP	Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001 >A>	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001					>A> NCE	Nov 29, 2017
					>A> NP	Apr 25, 2019
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002					>A> NCE	Nov 29, 2017
					>A> NP	Apr 25, 2019
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003					>A> NCE	Nov 29, 2017
					>A> NP	Apr 25, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CAREFILZOMIB - KYPROLIS</u>						
N 202714 001					I-722	Jan 21, 2019
					I-723	Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 205755 001 >A>	9309229	Jan 18, 2032	DS DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001 >A>	8932610	Mar 24, 2030	DP U-1578		>A> NC	Apr 29, 2019
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
>A>	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001					>A> D-163	Apr 22, 2019
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE	Mar 30, 2021
					>A> ODE	Mar 30, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6238994	May 17, 2019	DP			
	6238994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP	U-950		
	6462058	Jun 15, 2020	DS DP	U-951		
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP	U-950		
	6664276	Jan 30, 2023	DS DP	U-951		
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001 >A>	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002 >A>	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003 >A>	9308195	Sep 30, 2033	DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001 >A>	9302009	Oct 24, 2030	DP			
<u>ELBASVIR; GRAZOPREVR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP U-257			
	7390791	May 07, 2022	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	>A> 9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	>A> 5814639	Sep 29, 2015	DS DP	Y	>A> NCE	Nov 05, 2020
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	>A> 6642245	Nov 04, 2020	U-257			
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 6703396*PED	Sep 09, 2021				
	>A> 7390791	May 07, 2022	DS DP			
	>A> 7803788	Feb 02, 2022	U-257			
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE HYDROCHLORIDE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031	U-1781			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 5424286	Dec 01, 2016	U-1108			
	>A> 6479065	Aug 10, 2020	DP			
	>A> 6495164	May 25, 2020	DP			
	>A> 6667061	May 25, 2020	DP			
	>A> 6824822	Oct 09, 2022	DP			
	>A> 6858576	Jan 06, 2017	U-656			
	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6956026	Jan 07, 2018	U-687			
	>A> 7223440	Aug 31, 2021	DP			
	>A> 7456254	Jun 30, 2025	DP U-1223			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 7563871	Apr 15, 2024	DP			
	>A> 7612176	Apr 13, 2025	DP U-1223			
	>A> 7741269	Jan 07, 2018	U-1224			
	>A> 8216180	Jan 12, 2028	DP	Y		
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8439864	Mar 25, 2028	DP	Y		
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	>A> 9314447	May 31, 2033	DP U-1447			
	>A> 9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001				>A> NP		Apr 25, 2019
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8329680	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002				>A> I-731		Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001				>A> PC		Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002				>A> PC		Apr 25, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					>A> PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	>A> 9326982	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	>A> 9326982	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	>A> 9326982	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	>A> 9326982	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	>A> 9326982	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	>A> 9326982	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	>A> 9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	>A> 9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	>A> 9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	>A> 9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	>A> 9289391	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006 >A>	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007 >A>	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001 >A>	9296753	Oct 30, 2033	DS DP		I-729 >A> ODE	Mar 04, 2019 Mar 04, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001 >A>	9295639	Sep 30, 2029	U-1756			
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799 7544799*PED RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019 Jul 16, 2018 Jan 16, 2019	DS DP DS DP		Y	
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799 7544799*PED RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019 Jul 16, 2018 Jan 16, 2019	DS DP DS DP		Y	
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001 >A>	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002 >A>	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002 >A>	9011391 9233211	Mar 26, 2024 Mar 02, 2024	U-1832 DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001 >A>	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003 >A>	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001 >A>	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002 >A>	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003 >A>	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001					ODE	Oct 22, 2022
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 02, 2030	U-1806			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		>A> M-176	Apr 22, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					>A> PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					>A> M-175	Apr 05, 2019
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		>A> M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		>A> M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	>A> 6346532	Mar 27, 2022	DS DP			
	>A> RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	>A> 6346532	Mar 27, 2022	DS DP			
	>A> RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
<u>NITISINONE - ORFADIN</u>						
N 206356 001 >A>	9301932	Feb 02, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001 >A>	5792795	May 13, 2017	DP			
	>A> 5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623		Y	
	6489346	Jul 15, 2016	DP U-624		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-623		Y	
	6699885	Jul 15, 2016	U-624		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u>						
N 208090 001					>A> NP	Apr 26, 2019
<u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u>						
N 208090 002					>A> NP	Apr 26, 2019
<u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u>						
N 208090 003					>A> NP	Apr 26, 2019
<u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u>						
N 208090 004					>A> NP	Apr 26, 2019
<u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u>						
N 208090 005					>A> NP	Apr 26, 2019
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 001	7598271	May 04, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS DP			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS DP			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	>A> 7598271	May 04, 2025	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001					>A> NCE	Oct 22, 2017
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					>A> NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001					>A> NCE	Apr 29, 2021
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					>A> PC	May 18, 2016
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	>A> 9289446	Jun 22, 2019	DP U-116			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	>A> 7157456	Aug 28, 2024	DS DP U-1301			
	>A> 7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	>A> 7157456	Aug 28, 2024	DS DP U-1301			
	>A> 7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	>A> 7157456	Aug 28, 2024	DS DP U-1301			
	>A> 7157456	Aug 28, 2024	DS DP U-1302			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618			
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618			
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618			
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	>A> RE44186	Jul 31, 2023	DS DP U-995		>A> M-175	Apr 05, 2019
	>A> RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	>A> RE44186	Jul 31, 2023	DS DP U-995		>A> M-175	Apr 05, 2019
	>A> RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001					M-171	Feb 26, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001 >A>	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	>A> 9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-172	Feb 24, 2019
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	>A> 8546399	Jun 27, 2031	DS DP		>A> NCE	Apr 11, 2021
	>A> 9174982	May 26, 2030	U-1835		>A> ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	>A> 8546399	Jun 27, 2031	DS DP		>A> NCE	Apr 11, 2021
	>A> 9174982	May 26, 2030	U-1835		>A> ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	>A> 8546399	Jun 27, 2031	DS DP		>A> NCE	Apr 11, 2021
	>A> 9174982	May 26, 2030	U-1835		>A> ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>